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ABSTRACT 
Inflammatory bowel disease (IBD) effects approximately 1.6 million people in the United 
States with the incidence and prevalence increasing worldwide. All current treatments for IBD 
aim to simply mitigate the disease symptoms and come with negative consequences. A common 
comorbidity of IBD is inflammation-induced bone loss, which is characterized by increased bone 
resorption and decreased bone formation. Osteocytes, cells embedded in the bone matrix, are 
considered the primary regulatory cell type in bone; however, the role of osteocytes in 
inflammation-induced alterations in bone is unknown. The goals of the current project are to 
examine the role of osteocyte signaling proteins in inflammation-induced changes in bone 
turnover during chronic IBD and secondly, to explore lifestyle changes and therapeutic targets 
for IBD-induced alterations in bone.  
Male Sprague-Dawley rats (2 months old) were given gut inflammation via rectal 
instillations of 2,4,6-trinitrobenzenesulfonic acid (TNBS) dissolved in 30% ethanol while 
vehicle-treated rats received only 30% ethanol for four weeks. Osteoclast surfaces of cancellous 
bone were increased after TNBS while bone formation rate was decreased. These changes in 
bone turnover were coincident with higher osteocytes positive for pro-inflammatory markers, 
osteoclastogenesis regulators, and bone formation inhibitors. In a second experiment, TNBS and 
vehicle-treated rats were fed a moderately elevated soy protein diet during the experimental 
period. TNBS-treated animals fed the moderately elevated soy protein diet had reductions in 
osteoclast surfaces and increased bone formation rates corresponding with declines in osteocytes 
positive for pro-inflammatory factors. Finally, a third group of TNBS and vehicle-treated rats 
received exogenous administration of irisin, a protein released during exercise. TNBS-treated 
rats receiving irisin had significantly higher bone formation rates and lower osteoclast surfaces 
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than those receiving TNBS alone. Additionally, irisin-treated rats had lower osteocytes positive 
for pro-inflammatory factors.  
These results indicate that osteocytes respond to inflammatory signals and may 
orchestrate changes in bone turnover. Secondly, a moderately elevated soy protein diet reduced 
the inflammatory alterations in bone during chronic IBD. Additionally, designing methods to 
increase endogenous irisin, possibly through exercise, could potentially reduce inflammatory 
changes in bone during IBD. Finally, exogenous irisin administration is a potential novel 
therapeutic target for inflammation-induced bone loss. 
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1. INTRODUCTION AND LITERATURE REVIEW 
Bone is a dynamic tissue that adapts to its environment. In systemic physiology, the 
skeletal system plays many roles including protection, structure for locomotor ability, mineral 
homeostasis, and hematopoiesis. Bone tissue is sensitive to changes and disturbances in 
mechanical loads, energy availability and nutritional status, hormonal changes, and immune 
system alterations. Bone is continuously undergoing formation and resorption and, under normal 
physiological conditions, these processes are tightly regulated to ensure homeostasis and 
maintenance of bone mass. However, pathological disturbances can disrupt this tight balance of 
formation and resorption leading to bone loss and increased risk of fracture. Bone tissue 
adaptations are primarily carried out by three bone cells: osteoblasts, osteoclasts, and osteocytes.  
1.1 Cells of Bone 
Osteoclasts make up less than 1% of total bone cells and are responsible for degrading 
the mineralized matrix of bone leading to bone resorption. Derived from the monocyte-
macrophage lineage, osteoclasts are large, highly motile, multi-nucleated cells with a unique 
sealing zone which attaches to the bone surface. Within the sealing zone, a ruffled border of the 
cell releases proteolytic enzymes and hydrogen ions that degrade both the mineral and organic 
matrix of bone (1). Macrophage colony stimulating factor (M-CSF) and receptor activator of 
nuclear factor κB ligand (RANKL) are critical factors for osteoclastogenesis. RANKL binds to 
its receptor, RANK, and triggers osteoclastogenesis (2, 3). Another molecule, osteoprotegerin 
(OPG), has no signaling capabilities, but is capable of binding to RANKL. When OPG binds to 
RANKL, it prevents RANKL from interacting with RANK, decreasing osteoclast differentiation 
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(4; Figure 1.1). Therefore, the ratio of RANKL to OPG plays a critical role in osteoclast 
formation and activation.   
 
 
Figure 1.1: RANKL and OPG in osteoclastogenesis. RANKL stimulates osteoclast formation when binding to 
RANK while OPG binds to RANKL preventing its interaction with RANK and preventing osteoclast formation. 
 
 
 
Making up less than 5% of total bone cells, osteoblasts work in teams to deposit a protein 
matrix on bone surfaces which is then mineralized in a process known as bone formation. 
Osteoblasts are derived from mesenchymal progenitors that also can develop into chondrocytes, 
muscle cells, and adipocytes (2). Mature osteoblasts are non-proliferating cuboidal cells that 
secrete type 1 collagen and other proteins to form an organic matrix known as osteoid. This 
organic matrix can then be mineralized to form bone. Bone morphogenetic protein (BMP), 
transforming growth factor-β (TGFβ), and Wnt signaling factors are all involved in triggering 
osteoblastogenesis (5). Additionally, the transcription factors Runx2 and Sp7/osterix are critical 
for developing osteoblasts (2). The majority of osteoblasts likely undergo apoptosis after 
completing their tasks in bone formation; however, some osteoblasts are encased in the 
mineralized matrix of bone becoming osteocytes. 
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 Osteocytes are the longest living and most abundant bone cells making up 90-95% of 
the cells in bone tissue (6). Although osteocytes form when osteoblasts become buried in the 
bone matrix, osteocytes are a unique cell type with distinct features. Osteocytes are situated in 
lacuna within the mineralized matrix of bone and form long dendritic processes that extend out 
from their cell bodies into spaces known as canaliculi. Through these dendritic processes 
osteocytes form a network of communication with other osteocytes, cells on bone surfaces, and 
the marrow (6). Due to these vast communication networks, osteocytes are perfectly situated to 
sense the systemic environment as well as local signals within the bone and orchestrate specific 
adaptations. It is now understood that these cells, formerly considered simply place-holders in 
bone, are the master regulators of bone tissue. 
 Osteocytes can orchestrate the actions of osteoblasts and osteoclasts through several 
mechanisms. Osteocyte distress signals and apoptosis are potent signals to recruit osteoclasts to 
resorb bone in that region (7, 8). Certain signaling pathways like the Wnt/β-catenin pathway 
appear to be critical for maintaining osteocyte viability and, therefore, overall bone health (7, 9). 
Secondarily, osteocytes express and release proteins that signal to osteoblasts, osteoclasts, and 
other cells to orchestrate changes in response to the environment. Osteocytes express multiple 
factors important for the maintenance of mineral homeostasis including SOST, Phex, dentin 
matrix acidic phosphoprotein-1 (DMP1), and fibroblast growth factor 23 (FGF23) (7). Sclerostin, 
the protein encoded by the SOST gene, is one of the most well-studied osteocyte proteins. As an 
antagonist of the Wnt/β-catenin system, increased sclerostin expression leads to a suppression of 
osteoblasts and, therefore, is a negative regulator of bone formation (10, 11). Mice 
overexpressing SOST have low bone mass (11) and transgenic mice lacking sclerostin have 
increased bone formation rate and bone strength (12). Osteocytes also express RANKL and 
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OPG, the critical regulators of osteoclastogenesis (2). It is now appreciated that osteocyte 
RANKL is the primary source of RANKL needed for osteoclast formation for bone remodeling 
(13, 14). 
 One of the most well examined actions of osteocytes is their mechanosensory 
capabilities. It has long been known that bone adapts to the mechanical strains placed on it; 
however, only in the past couple decades has the important role of the osteocyte been explored. 
Osteocytes sense mechanical strains through tissue strain, fluid flow shear stress through the 
lacuna-canalicular network, and movement on cell bodies and dendrites (9, 15). These 
mechanosensory signals on osteocytes can trigger them to release various proteins that impact 
bone turnover. For example, a lack of mechanical loading results in increased sclerostin while 
increased loading decreases osteocyte sclerostin (16, 17). RANKL and OPG are also 
mechanosensitive osteocyte proteins (18); for example, osteocyte RANKL release is increased 
due to lack of mechanical loading. Furthermore, mice lacking osteocyte RANKL are protected 
from disuse-induced bone loss (14). Additionally, osteocytes release insulin-like growth factor-I 
(IGF-I) and interleukin-6 (IL-6) in response to increased mechanical loading, leading to 
signaling to osteoblasts to increase bone formation (17, 19-21; Figure 1.2). The role of 
osteocytes in the mechanosensory capabilities of bone highlight the important role these cells 
play in bone adaptations to the environment. 
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Figure 1.2: Response of osteocytes to mechanical unloading and loading. Mechanical unloading (left) and 
mechanical loading (right) impact osteocyte proteins controlling bone formation and bone resorption. 
 
 
1.2 Inflammation and Bone 
 Another environmental stimulus that impacts skeletal tissue is inflammation. 
Inflammation is a complex response of the immune system to an injury or threat, where 
components of the immune system try to minimize and repair damage caused by the 
threat/injury. The innate arm of the immune system responds immediately to threats and damage 
in a non-specific manner while the adaptive immune system takes time to respond, but has 
specific and long-lasting memory to unique pathogens. Both arms of the immune system, once 
activated, release soluble factors known as cytokines. Many cytokines are also released by 
parenchymal cell types to aid in the immune response. Cytokines regulate the intensity, direction, 
and duration of the immune response by stimulating or inhibiting various cell types, regulating 
the secretion of other cytokines or antibodies, and sometimes can program cell death in the target 
cell (22). Cytokines are, therefore, capable of inducing communication within a vast network of 
cells. In some cases, the immune system remains active due to loss of ability to recognize “self” 
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vs. “non-self” resulting in autoimmunity which leads to chronic inflammation and a constant 
barrage of cytokines. Cytokines are sometimes classified by the type of T helper lymphocyte 
they are largely produced by – Th1, Th2, or Th17. Th1 cells produce many cytokines including 
interferon-γ (IFN-γ) and the tumor necrosis factor (TNF) cytokines while Th2 cells produce 
factors such as interleukin-4 (IL-4) and interleukin-10 (IL-10) among others (23). Th17 are the 
most recently identified class of T helper lymphocytes which primarily release interleukin-17 
(24). While these classifications have merit, the immune system is vastly complex and no 
cytokine perfectly fits into a single grouping. Nonetheless, organ-specific autoimmune diseases 
like Crohn’s disease are often Th1-driven while allergen-specific conditions are often Th2-driven 
(23).  
 The interaction between the immune system and skeletal tissue has recently garnered 
interest, leading to the development of a field of study known as osteoimmunology (25-28). This 
cross-talk between the immune system and bone has become more evident with the accumulating 
knowledge of the shared signaling pathways between immune cells and osteoclasts, which are 
essentially specialized macrophages which develop from the same lineage as immune cells. 
Additionally, immune cells develop in the marrow of bone in the same environment as 
osteoclasts and osteoblasts. The first molecule to establish the concept of crosstalk between these 
two systems was RANKL (25, 27). This molecule is not only a key factor in osteoclastogenesis, 
but also plays critical roles in immune function. Bone biologists and immunologists 
unexpectedly found that the long sought after osteoclast differentiation factor was the same 
factor expressed by T cells to stimulate dendritic cells (27). RANKL is expressed by many 
immune cells including T cells and B cells, while its receptor RANK is expressed on 
macrophages and monocytes (29). Some candidate roles for RANKL in the immune system 
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include stimulating antigen presentation to T cells, modulation of T regulatory cells, 
development of B cells, and lymph node development (29). Mice lacking RANKL have both 
severe osteopetrosis due to a lack of osteoclasts as well as a deficiency of B cells and a lack of 
peripheral lymph nodes (30). Importantly, RANKL, RANK, and OPG are all members of the 
tumor necrosis factor (TNF) and TNF receptor superfamilies with broad expression throughout 
the body and association with immune cells (31). Therefore, these molecules are not simply 
osteoclastogenesis factors and must be viewed in their broader context of immune and systemic 
physiology.  
 Beyond RANKL/RANK/OPG, multiple other immune factors influence bone 
homeostasis. In particular, cytokines can interact with bone cells leading to increased bone 
resorption that, over time, leads to inflammatory bone loss (32). Multiple conditions with chronic 
inflammation are associated with low bone mass including rheumatoid arthritis, where there is 
both local bone erosion and systemic bone loss (33, 34), systemic lupus erythematosus (35), 
psoriasis and psoriatic arthritis (36), ankylosing spondylitis (37), and celiac disease (38). A key 
driver of inflammation is tumor necrosis factor-α (TNF-α). TNF-α is a strong stimulator of 
osteoclastogenesis even with extremely low levels of RANKL (39, 40). In a cell culture model, 
Lam et al demonstrated that less than 1% of the RANKL needed to induce osteoclastogenesis 
was necessary in the presence of TNF-α to induce a robust increase in osteoclast development 
(40). TNF-α also mediates and synergizes with RANKL to increase osteoclastogenesis (41, 42). 
TNF-α also increases the production of OPG (43). Another cytokine, interleukin-6 (IL-6), has 
equivocal roles in bone physiology, but appears to not stimulate osteoclasts alone unless other 
cytokines are present normal physiological conditions; however, with TNF-α, IL-6 synergizes to 
stimulate osteoclasts and increase production of RANKL and OPG (42; Figure 1.3). Cytokines 
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classified as Th2, often considered “anti-inflammatory” in nature, remain more poorly 
understood in the context of bone physiology. Both interleukin-4 (IL-4) and interleukin-10 (IL-
10) have been shown to inhibit osteoclasts and reduce RANKL in cell culture models (44-47). In 
vivo models reflect a more complex picture with mice lacking IL-10 having low bone mass and 
increased fragility (48). This observation suggests that IL-10 and also likely IL-4 have more 
complex roles in skeletal physiology than simply inhibiting osteoclasts.  
 
 
Figure 1.3: Proposed interactions of TNF-α, RANKL, OPG, and IL-6 on osteoclast formation. TNF-α strongly 
stimulates osteoclastogenesis as well as stimulating and synergizing with RANKL and IL-6 to enhance osteoclast 
formation. TNF-α also stimulates OPG. 
 
 
 
 Pro-inflammatory factors also interact with osteoblast development and function. 
TNF-α inhibits osteoblast genes and differentiation factors and inhibits bone collagen synthesis 
(41, 49, 50). Runx2, a key factor in osteoblast differentiation, is degraded by TNF-α; mice 
injected with TNF-α have decreased Runx2 protein levels (51). Additionally, TNF-α inhibits the 
anabolic signals of IGF-I in osteoblasts (41, 52). Osteoblast apoptosis is induced in the presence 
of TNF-α (41, 53). Finally, sclerostin, the inhibitor of osteoblast formation, is transcriptionally 
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activated by TNF-α (54; Figure 1.4). The role of IL-6 in osteoblasts in the context of 
inflammation is unknown; however, IL-6 appears to be able to signal to osteoblasts in the 
absence of TNF-α in conditions of increased mechanical loads (17, 19). The role of IL-10 and 
IL-4 on osteoblast differentiation and function is uncertain. Mice lacking IL-10 have low bone 
formation rate (48), indicating some potential role of IL-10 with osteoblasts. 
 
 
Figure 1.4: Influence of TNF-α on osteoblasts. TNF-α inhibits the anabolic signals of IGF-I on osteoblasts. TNF-α 
also directly inhibits osteoblasts while stimulating sclerostin which also inhibits osteoblasts. 
 
 
 
 There is a great lack of literature on how inflammation impacts osteocytes, even 
though osteocytes are considered to be the master regulators of bone cell activity. What is known 
is that TNF-α can trigger osteocyte apoptosis (55) and that TNF-α is a transcriptional activator of 
the osteocyte protein, sclerostin (Baek; Figure 1.5). Due to their central role in orchestrating 
changes in bone turnover during increased or decreased mechanical loads and the fact that many 
of these same factors are associated with inflammatory processes (Table 1.1), it seems highly 
probable that osteocytes also play a central role in orchestrating adaptations to inflammatory 
signals.  
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Figure 1.5: TNF-α interactions with osteocytes. TNF-α induces osteocyte apoptosis and increases sclerostin 
expression. 
 
 
 
Table 1.1: Factors associated with inflammatory bone loss, their interactions with bone cells, and expression in 
osteocytes. 
Factor Role in Bone Expression in Osteocytes 
Tumor necrosis factor-α 
(TNF-α) 
Stimulates osteoclast 
formation, suppresses 
osteoblasts, triggers osteoblast 
and osteocyte apoptosis 
Unknown 
Interleukin-6 (IL-6) Equivocal role in bone, with 
TNF-α synergizes osteoclast 
formation, may stimulate 
osteoblasts alone 
Yes; known to be 
mechanosensitive 
Interleukin-10 (IL-10) Inhibits osteoclastogenesis Unknown 
Interleukin-4 (IL-4) Inhibits osteoclastogenesis, 
inhibits RANKL 
Unknown 
Sclerostin Inhibits bone formation, 
transcriptionally activated by 
TNF-α 
Yes; known to be 
mechanosensitive 
Receptor activator of 
nuclear factor ΚB ligand 
(RANKL) 
Final step in 
osteoclastogenesis, activated by 
TNF-α, synergizes with TNF-α 
to increase osteoclast formation 
Yes; known to be 
mechanosensitive 
Osteoprotegerin (OPG) Binds to RANKL preventing 
osteoclastogenesis, stimulated 
by TNF-α 
Yes; known to be 
mechanosensitive 
Insulin-like growth factor-I 
(IGF-I) 
Stimulates osteoblasts and 
increases bone formation rate, 
inhibited by TNF-α 
Yes; known to be 
mechanosensitive 
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1.3 Inflammatory Bowel Disease and Bone 
 One such chronic inflammatory condition with skeletal morbidities is inflammatory 
bowel disease (IBD). The primary IBD conditions are ulcerative colitis and Crohn’s disease, 
which are caused by prolonged inflammation along all or parts of the digestive tract. 
Approximately 1.6 million people in the United States have IBD and the incidence and 
prevalence is increasing globally (56-58). Particularly of concern is the increasing incidence of 
pediatric IBD, especially Crohn’s disease (59). Pediatric IBD is characterized by more extensive 
disease and lifelong complications (56). While the exact etiology of IBD remains largely 
unknown, it is considered an autoimmune condition in which the immune system mounts an 
attack against tissues within the digestive tract leading to chronic inflammation; however, 
genetic and environmental factors are also likely involved in the development of the pathology 
(60-64). IBD pathogenesis is believed to be largely driven by Th1 cytokines like TNF-α (61, 62, 
65, 66).  
Beyond the inflammation, significant damage, and complications that can arise within the 
gastrointestinal tract due to IBD, the inflammatory insult initiated in the gut can lead to multiple 
extra-intestinal complications that can lead to additional morbidity (67). One such complication 
is bone loss which is a leading comorbidity of IBD (68, 69). Osteopenia (T score between -1 and 
-2.5 below healthy age-matched controls) and osteoporosis (T score below -2.5) prevalence are 
common in patients with IBD, with reported incidence of osteoporosis in this population ranging 
from 12-70% (68, 70, 71). Of a cohort of forty-nine patients with IBD (average age = 37), 42% 
met the criteria for osteopenia in the femoral neck while 41% met the criteria for osteoporosis. In 
this same cohort, 34% had osteopenia in the lumbar spine and 42% had osteoporosis in this bone 
site (72). Other studies have shown similar loss of bone mineral density at the lumbar spine and 
 12 
 
femoral neck (73). Osteopenia is also common in children with IBD, a population rarely plagued 
with low bone mass (74, 75). At time of diagnosis, many patients with IBD already have lower 
bone mineral density than healthy controls (76, 77) and decreased trabecular BMD and cortical 
section modulus (75). Children just 35 days after diagnosis with Crohn’s disease had low total 
body bone mineral content for age and sex as well as reduced trabecular volumetric BMD at the 
tibia metaphysis and thin cortices at the tibia diaphysis (78). This is particularly concerning since 
approximately 35% of total bone mineral accrual occurs during the four years of adolescence 
surrounding the age of peak linear growth velocity (79). Thus, during a time when most 
adolescents are rapidly gaining bone mineral, those with IBD are losing bone mass. This bone 
loss in patients with IBD can be rapid. In a cohort of 54 adults with IBD, the mean loss of 
vertebral BMD was 3% over the course of a year, but eleven of the 54 patients had bone loss 3-
fold greater than the mean, indicating a wide range of rates of bone loss (80). Of the conditions 
within IBD, Crohn’s disease is often associated with more severe bone loss compared to 
ulcerative colitis, particularly in cancellous bone, the three-dimensional lattice-like structure in 
the vertebral bone and ends of long bones (81).  
Concurrent with low bone mass and increased rates of bone loss, patients with IBD have 
increased serum or urinary measures of bone resorption and decreased circulating measures of 
bone formation (69, 82-85). Given the pro-inflammatory status in IBD patients, this suppression 
in formation and increase in resorption in patients with IBD indicates a systemic effect of 
inflammation on bone cell activity that promotes net bone loss. Additionally, serum RANKL and 
OPG are dysregulated in IBD patients, with increases particularly in circulating OPG levels (69, 
86-89). Of cytokines, serum IL-6 is elevated in IBD patients (72, 90-92). Other cytokines, like 
TNF-α, are often not different in the serum (92). One study treated fetal rat parietal bones with 
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serum from newly diagnosed children with IBD and discovered uneven mineralized bone matrix, 
altered osteoblast morphology, and disorganized osteoblasts; however, treatment with an IL-6 
neutralizing antibody prevented these changes (92). Therefore, pro-inflammatory cytokines like 
IL-6 are believed to be drivers of the altered bone turnover seen in IBD. 
With decreased formation, increased resorption, and low bone mass, patients with IBD 
are at an increased risk of fractures. Indeed, IBD patients at any age have 40% greater fracture 
incidence than the general population (93). In comparison, the fracture risk over an entire 
lifetime for white postmenopausal women, the population at the greatest risk for osteoporosis, is 
30-40% (94, 95). Vertebral fractures are particularly common in IBD even in patients with 
normal BMD (96), with prevalence strikingly high at approximately 22% even in those aged less 
than 30 years (97). Incidence of hip and vertebral fractures are higher in patients with Crohn’s 
disease versus ulcerative colitis (98), reflecting the more significant bone loss that is often seen 
in Crohn’s disease patients. Disease severity determined by the number of disease symptoms 
predicts fracture incidence in IBD patients (98).  
It is important to note bone loss due to IBD is not caused by corticosteroid use, a 
frequently used therapeutic agent in IBD. First, as previously mentioned, newly diagnosed 
patients who have yet to receive any treatments have lower bone mass than healthy controls (75-
77). Another study demonstrated that low BMD in IBD patients did not correlate with current or 
previous corticosteroid use (82). Likewise, a significant portion of corticosteroid naïve Crohn’s 
disease patients have osteopenia (70). Vertebral fractures occur at the same rates in Crohn’s 
disease patients whether or not they use corticosteroids (96). In pediatric patients, bone mass was 
inversely correlated with disease activity indices (90) and fracture incidence is predicted by 
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disease severity as well (98), indicating it is the disease itself that leads to bone loss and not 
complications due to corticosteroid treatment.  
1.4 IBD and Bone in Animal Models 
 Multiple animal models can be utilized to examine the mechanisms of IBD pathology 
and to experiment with novel therapeutics. There are many transgenic mouse models that 
develop symptoms similar to human colitis or Crohn’s disease (99-101). For example, 
interleukin-10 deficient mice have a primarily Th1-driven response with inflammation in both the 
small intestine and colon (99). In another model, TNFΔARE transgenic mice, elevated TNF-α due 
to depressed mRNA degradation triggers the development of inflammation in the proximal colon 
and ileum similar to human Crohn’s disease (99, 100). There are two predominantly used 
chemically-induced models of gut inflammation that can be utilized in both mice and rats. A 
haptenizing agent named 2,4,6-trinitrobenzenesulfonic acid (TNBS) can be dissolved in ethanol 
and instilled rectally to induce gut inflammation (101). The ethanol breaks the mucosal barrier in 
the colon while the TNBS makes the colonic cells and potentially the gut microbiota 
immunogenic to the host, triggering an immune reaction (99, 101). Cytokine profiles with 
TNBS-induced IBD are similar to human Crohn’s disease (99). Prepubertal rats treated with 
TNBS had elevated serum IL-6 levels similar to those seen in children with Crohn’s disease 
(102). The second chemically induced model utilizes dextran sodium sulfate (DSS) dissolved in 
drinking water. It is believed DSS is directly toxic to the epithelial cells of the colon, thereby 
initiating an inflammatory response (99, 101). DSS typically induces inflammation along the 
colon and, therefore, may be more analogous to human colitis (100). While murine TNBS-
induced IBD is largely Th1 driven, DSS-induced IBD in mice shifts from a Th1 acute phase to 
Th2 as the disease becomes chronic (103). 
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Few studies have addressed bone outcomes in animal models of IBD. One study 
examined two weeks of DSS-induced gut inflammation in mice, demonstrating that the DSS-
induced IBD lead to low bone mass, depressed bone formation, and increased osteoclast number 
(104). Two other studies found suppressed osteoblastic activity and bone formation rate due to 
chemically-induced IBD that was reversible with recovery from IBD (105, 106). In general, there 
is a lack of studies examining chronic IBD in animal models, as most studies focus on much 
more acute time frames (5-14 days). Since IBD is a chronic disease, studies addressing more 
long-term outcomes are needed to understand the pathophysiology of prolonged gut 
inflammation as well as the impact on bone. . Additionally, there are no published data 
addressing the role of osteocyte proteins in mediating the alterations in bone turnover that result 
in IBD-induced bone loss.  
1.5 Current Treatments for IBD 
IBD is a chronic condition that currently has no cure. All current treatments aim to 
simply mitigate disease symptoms and improve the quality of life of patients. Corticosteroids can 
be used to decrease inflammation; however, the negative effect of corticosteroids on bone health 
is well documented, with long-term use associated with development of osteoporosis (107, 108). 
Previously, immunosuppressant agents like azathioprine were a common therapy for IBD; 
however, azathioprine can cause leucopenia and bone marrow suppression or toxicity leading to 
potentially lethal complications (109). A great advance in treating chronic inflammatory 
conditions like rheumatoid arthritis and Crohn’s disease came with the development of anti-
cytokine therapies, specifically anti-TNF (110). Anti-TNF treatments (infliximab, etanercept, 
adalimumab) often lead to reductions in other cytokines and chemokines including IL-6 (110). 
With regards to bone, anti-TNF therapy has been shown to improve BMD (111) and systemic 
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measures of bone formation (112) in patients with IBD. However, there are multiple unknown 
factors with anti-TNF treatment, including its impact on bone parameters and fracture risk with 
long-term use (113). Additionally, whether the cessation of anti-TNF treatment is negative to 
bone health is uncertain (113). Other complications of anti-TNF treatment make its use, although 
valuable in many autoimmune inflammatory conditions, not ideal. There is nearly a doubled risk 
of developing a serious infection while on anti-TNF therapy (114, 115) and a dose-dependent 
increased risk of developing malignancies (115). Additionally, development of autoantibodies 
can occur with anti-TNF pharmaceuticals, which can interfere with the pharmacokinetics of the 
drug and, in some rare cases, lead to the development of other autoimmune conditions (116, 
117). Other anti-cytokine treatments, like anti-IL-6, have been explored for use in IBD (118), but 
are not currently available to patients. 
Treatments specific to bone typically fall into two categories – anti-resorptive therapies 
and anabolic therapies. Bisphosphonates are one class of anti-resorptive agents that inhibit bone 
resorption by triggering osteoclast apoptosis. Risedronate, one type of bisphosphonate, improved 
bone mass at the hip and spine in IBD patients with low bone mass (119). Bone loss due to 
another inflammatory condition, inflammatory arthritis in human TNF transgene mice, was 
retarded due to treatment with zoledronate, another bisphosphonate, but it had no effect on 
inflammation (120). A common side effect of some bisphosphonate treatments is gastrointestinal 
complications, reported in close to 50% of patients, often resulting in low adherence to treatment 
(121). Gastrointestinal complications due to bisphosphonates in IBD may make adherence even 
more difficult than for other populations of patients. Another anti-resorptive drug, denosumab, 
works by binding RANKL, therefore preventing osteoclast formation. In patients with 
rheumatoid arthritis who experience inflammatory bone loss, denosumab combined with the 
 17 
 
immunosuppressant, methotrexate, helped maintain joint structure and improved bone turnover 
markers, but had no effect on disease activity (122). Intermittent parathyroid hormone 
(teriparatide) treatment is the only approved anabolic agent for bone at this time. There are no 
trials evaluating its effectiveness in preventing bone loss in IBD. Another anabolic treatment 
currently in clinical trials, an antibody against sclerostin, was examined in an animal model of 
IBD and was found to improve bone mass, but had no impact on histological changes in the 
colon (123). In general, the few studies that have examined bone specific therapies in 
inflammatory disorders show potentially improved bone mass, but no changes in the underlying 
pathology or inflammatory status. 
There is a great need for holistic treatments for IBD that mitigate the gut pathology as 
well as the bone comorbidity. Current anti-inflammatory treatments like corticosteroids and anti-
TNF therapy mitigate the inflammatory status, but lead to significant negative side effects and 
consequences like increased risk of serious infections. Additionally, these treatments are either 
already known to not be safe in the long-term (i.e. corticosteroids) or have unknown implications 
with long-term use. To date, bone-specific therapies appear to only impact bone itself and not the 
actual inflammatory disease causing the bone loss, which increases the likelihood of needing 
multiple concurrent pharmacological therapies and thereby increasing the risk of negative side 
effects and drug interactions. Therefore, novel therapeutics and lifestyle/dietary interventions for 
IBD that influence the entire system, gut and bone and all other extraintestinal organs influenced 
by inflammation, would be of great value in mitigating disease symptoms, preventing 
comorbidities, and improving the quality of life of patients. 
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1.6 Specific Aims of Current Studies 
 Inflammation-induced bone loss from IBD causes increased bone resorption and 
suppressed bone formation. While the systemic actions of multiple cytokines, such as tumor 
necrosis factor-α (TNF-α) and interleukin-6 (IL-6), are more well understood in inflammatory 
states, how these factors are altered specifically in bone are unknown. To date, no study has 
comprehensively addressed the osteocyte-specific response in the pathogenesis of IBD-induced 
inflammation and bone loss. Understanding the role of osteocytes and their regulatory proteins 
will provide greater insight into the mechanisms behind IBD-induced bone loss and subsequent 
targets for elucidating countermeasure efficacy. Secondly, as previously discussed, there is a 
great need for holistic treatments for IBD to prevent gut and bone damage and improve quality of 
life. Non-pharmacological measures to treat bone loss particularly with reference to 
inflammatory mechanisms have not been fully explored. We propose examining both a dietary 
intervention and exogenous treatment with irisin, a factor released during exercise, in an animal 
model of chronic IBD. No published investigations have addressed these proposed interventions 
in chronic IBD or their influence on bone outcomes. The objectives are as follows:  
Specific Aim 1 (SA1): Determine the impact of inflammation in a chronic IBD rodent 
model on bone turnover, osteocyte inflammatory cytokines, and osteocyte regulators of bone 
turnover. I hypothesize chronic IBD will result in increased osteoclast surfaces, decreased bone 
formation rate, increased osteocyte TNF-α and IL-6, decreased osteocyte IGF-I, alterations in 
osteocyte RANKL/OPG, and increased osteocyte sclerostin. The changes in osteocyte proteins 
will correlate with changes in bone formation rate and osteoclast surface.      
Specific Aim 2 (SA2): Evaluate the impact of a 35% soy protein isocaloric diet during 
chronic IBD on bone turnover, osteocyte inflammatory cytokines, and osteocyte regulators of 
 19 
 
bone turnover. I hypothesize a moderately elevated soy protein diet will decrease pro-
inflammatory cytokines and favorably alter osteocyte regulators of bone turnover. These changes 
will correspond with increases in bone formation rate and reduced osteoclast surfaces.           
Specific Aim 3 (SA3): Evaluate the impact of exogenous treatment with recombinant 
irisin during chronic IBD on bone turnover, osteocyte inflammatory cytokines, and osteocyte 
regulators of bone turnover. I hypothesize treatment with irisin will decrease osteoclast surfaces 
and exert an anabolic effect on bone leading to increased bone formation rate. Additionally, 
exogenous irisin treatment during chronic IBD will decrease pro-inflammatory cytokines and 
favorably alter osteocyte regulators of bone turnover.  
The work proposed in these specific aims will allude to the involvement of osteocytes in 
inflammation-induced bone loss as well as characterize potential holistic treatments for IBD. 
Applications of this project can aid in dietary recommendations, the potential development of 
exercise therapies, and the development of new pharmacologic treatments for IBD. In addition, 
these results could potentially be applied to other chronic systemic inflammatory conditions like 
autoimmune conditions and spinal cord injury. 
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2. INFLAMMATORY BOWEL DISEASE IN A RODENT MODEL ALTERS 
OSTEOCYTE PROTEIN LEVELS CONTROLLING BONE TURNOVER* 
Inflammatory bowel disease (IBD) is a group of diseases, including Crohn’s disease and 
ulcerative colitis, that affects approximately 1.6 million people in the United States and 2.2 
million in Europe (1) with its incidence and prevalence increasing worldwide (2, 3). 
Inflammation occurring along all or multiple sections of the gastrointestinal (GI) tract or in 
specific sections (i.e. colon in ulcerative colitis) leads to chronic systemic inflammation (4). One 
common comorbidity seen in IBD patients is bone loss (4-8). Low bone mass affects 40-50% of 
patients with IBD with 10-20% having clinical osteoporosis (5, 6, 9). Not surprisingly, there is a 
40% greater fracture incidence in patients with IBD (10). Therapeutic use of corticosteroids by 
these patients can further exacerbate bone loss, but significant bone loss in IBD occurs even in 
those not on corticosteroid therapy (11, 12). Rapid loss of vertebral bone occurs in IBD and 
vertebral fractures are estimated to develop in up to 1 in every 5 adults (13-15). Similarly, bone 
loss observed at the clinically relevant fracture site of the femoral neck mirrors bone loss seen in 
vertebral bone (7, 16). Although IBD is most prevalent in young adults and adolescents, the 
incidence of diagnosis in children is increasing (17). This is a critical stage in bone development 
and children diagnosed with Crohn’s disease experience losses in cancellous volumetric bone 
mineral density at the tibia (18) as well as decreased total body and femoral neck bone mineral 
content (19).   
                                                 
* Reprinted with permission from “Inflammatory bowel disease in a rodent model alters osteocyte protein levels 
controlling bone turnover” by Metzger CE, Narayanan A, Zawieja DC, Bloomfield SA, 2017. J Bone Miner Res, 
32(4), 802-813, Copyright 2017 by John Wiley and Sons. 
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 It is generally believed systemic inflammation due to IBD leads to bone loss by 
stimulating osteoclast activity (increasing bone resorption) and inhibiting osteoblast activity 
(decreasing bone formation) (20). Systemic increases in circulating pro-inflammatory cytokines 
coincide with IBD (4, 5, 21) particularly during symptom flare-ups. Tumor necrosis factor-α 
(TNF-α), a potent pro-inflammatory cytokine, plays a crucial role in inflammatory bone loss by 
stimulating osteoclastogenesis and inhibiting osteoblast function (22, 23). TNF-α also indirectly 
lowers bone formation by suppressing the anabolic growth factor, insulin-like growth factor-I 
(IGF-I) (22). Serum IGF-I concentrations are 21% lower in IBD patients compared to healthy 
controls (24). Additionally, interleukin-6 (IL-6) concentrations are significantly elevated, up to 
34-fold higher, in serum of both children and adults with IBD (9, 21, 24). Although the exact 
role of IL-6 in bone turnover is equivocal, in the context of IBD in vitro studies have implicated 
it as a prominent factor leading to bone loss (21). Although interleukin-10 (IL-10) was originally 
described as an anti-inflammatory cytokine, recent studies have shown that its 
immunomodulatory effects are complex, as well as tissue- and context-dependent (25). Aside 
from its role in gut immunomodulation, IL-10 has been shown to increase in serum concentration 
of patients with IBD (26, 27). Since IL-10 inhibits osteoclastogenesis (28, 29), it is hypothesized 
that elevated serum IL-10 may be a compensatory mechanism with respect to bone to prevent 
excessive bone resorption. Another proposed mechanism for the increase in bone resorption in 
IBD is alterations in receptor activator of nuclear factor κ-B ligand (RANKL) and 
osteoprotegerin (OPG); both are the final regulatory step in osteoclastogenesis. Interestingly, 
OPG concentrations, rather than RANKL concentrations, are elevated in serum of patients with 
IBD and are inversely correlated with low BMD (4, 6, 30-32).   
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 Research over the past decade has revealed how osteocytes, bone cells embedded in 
the bone matrix, are critical regulators of bone metabolism releasing factors influencing the 
development and actions of both osteoblasts and osteoclasts (33). While the role of osteocytes in 
bone homeostasis is increasingly appreciated, the impact of systemic inflammation on osteocytes 
is poorly understood. Sclerostin, an osteocyte protein which inhibits the Wnt/β-catenin signaling 
pathway in osteoblasts, is upregulated by TNF-α (34) suggesting a potentially significant link 
between inflammation and osteocyte function. Besides sclerostin, many of the systemic 
circulating factors implicated as players in IBD-induced bone loss are proteins expressed by 
osteocytes including RANKL, OPG, IL-6, and IGF-I (35-39). Previously, these osteocyte 
proteins have been primarily studied in the context of loading and unloading and mechanical 
strain (35, 37, 39). How these osteocyte proteins are altered in response to inflammation at 
distant sites (i.e. gastrointestinal systems) and how these osteocyte protein alterations influence 
osteoblast and osteoclast activity in bone is unknown.   
Goals of this current project were to examine the impact of these factors, all of which are 
altered in IBD patients’ serum in clinical trials, on tissue-specific bone outcomes in an 
established rodent model of IBD, specifically focusing on the osteocyte response. To our 
knowledge, this is the first investigation to examine the role osteocytes might play in mediating 
the loss of bone in the context of IBD. We hypothesized that 4 weeks of IBD in young male rats 
would result in bone loss, increased bone resorption, and decreased bone formation. In addition, 
we hypothesized the prevalence of osteocytes positive for TNF-α, IL-6, IL-10, RANKL, OPG, 
and sclerostin would be higher in IBD, while prevalence of osteocytes positive for IGF-I would 
be lower compared to age-matched vehicle treated controls.   
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2.1 Materials and Methods 
Animals:  Sixteen two-month-old male Sprague Dawley rats (weighing 250-274 
grams) were purchased from Charles River Laboratories (Houston, TX), pair housed in a room 
with 12 hour light-dark cycles, and allowed ad libitum access to LabDiet 5053 rodent chow 
(LabDiet; St Louis, MO) and water. After one week of acclimation, rats were randomly divided 
into TNBS and vehicle control (n=8 per group).  Tissues were collected from these animals for 
this study, but the parent protocol using different tissues set the group size; however, statistical 
power analyses for our outcomes showed n=4 as sufficient power for bone formation rate 
analyses and n=6 for all other histomorphometric and histological analyses. Gut inflammation 
was induced by 250-274 uL (1 uL/gram body weight) rectal instillations of 2,4,6-
trinitrobenzenesulfonic acid (TNBS; Sigma Aldrich, St Louis, MO) in 30% ethanol:DiH2O 
solutions (40-42). The 30% ethanol was used to disrupt the mucosal barrier while the haptenizing 
agent, TNBS, stimulated an immune response leading to gut inflammation. At days 1, 7, 14, 21, 
and 26 days non-fasted rats were anesthetized via inhaled isoflurane with a precision vaporizer 
and given enemas with either vehicle (30% ethanol:DiH2O) or TNBS (30mg/kg trinitrobenzene 
sulfonic acid dissolved in 1mL 30% ethanol:DiH2O) using an 18-gauge catheter with a blunted 
end inserted 7.5 cm into the rectum. The anus was held closed for 5 minutes after instillation to 
control the contact of the enema solution with the colon, after which animals were allowed to 
recover from anesthesia. Animal handling could not be completely blindly due to the nature of 
the study, but all collected tissues were analyzed blindly by the investigators. Fluorochrome 
calcein labels (Sigma Aldrich, St Louis, MO) were injected intraperitoneally 9 and 2 days prior 
to termination to label mineralized surfaces on bone. At day 28 animals were anesthetized via 
inhaled isoflurane, euthanized via thoracotomy, and tissues collected. All animal procedures 
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were approved by Scott & White Healthcare and Texas A&M Health Science Center 
Institutional Animal Care and Use Committees and conform to the NIH Guide for the Care and 
Use of Laboratory Animals.     
Colon histopathology: Upon removing rat large intestinal loops, sections were cut 
from the colon (3 cm distal to the caecum), flushed of fecal matter, washed in DPBS, and fixed 
in 4% paraformaldehyde for 2 hours at room temperature; one more brief wash in PBS occurred 
before tissue was placed in 70% ethanol to dehydrate overnight at 4°C. Sections were then 
further dehydrated via a Thermo-Scientific STP 120 Spin Tissue Processor, paraffinized via a 
Thermo Shandon Histocenter 3 Embedding tool, sectioned (6 μm) via microtome, and adhered to 
positively charged glass slides for staining via Hematoxylin and Eosin (H&E) staining solutions. 
Colon damage scoring was performed on a 0-4 scale (0 being normal, and 4 being severe damage 
or alteration) for epithelial cell loss, crypt loss, edema, and cellularity. 
Peripheral Quantitative Computed Tomography:  Right tibia were saved in phosphate 
buffered saline in -35○ C. Once thawed, ex vivo pQCT scans of the proximal tibia metaphysis 
(mixed cortical and cancellous bone site) and mid-shaft tibia (purely cortical bone site) were 
completed on a Stratec XCT Research-M device (Norland Corp., Fort Atkinson, WI). 
Metaphyseal volumetric BMD was measured at the proximal tibia from 4 slices located at least 1 
mm distal of the growth plate. Three contiguous slices were averaged to provide one value for 
each variable at the proximal tibia metaphysis. One mid-shaft tibia slice was taken at 
approximately 50% of the total bone length. Scans were completed at 2.5 mm/sec scan speed, 
100 μm voxel resolution, and 0.5 mm slice thickness. Measures obtained from the ex vivo pQCT 
scans include cortical and cancellous volumetric bone mineral density (vBMD). 
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Dynamic and static cancellous histomorphometry: For cancellous histomorphometry 
measures, undemineralized proximal tibia and 4th lumbar vertebra were fixed in 4% phosphate-
buffered formalin for 24 hours and then subjected to serial dehydration and embedded in methyl 
methacrylate (Aldrich M5, 590-9, St. Louis, MO, USA). Serial frontal sections were cut 8 μm-
thick and left unstained for fluorochrome calcein label measurements. The histomorphometric 
analyses were performed using OsteoMeasure Analysis System, version 3.3 (OsteoMetrics, Inc., 
Atlanta, GA, USA). A defined region of interest was established approximately 500 μm from the 
growth plate and within the endocortical edges encompassing approximately 8 mm2 at 20x 
magnification. Total bone surface (BS), single-labeled surface (sLS/BS), double-labeled surface 
(dLS/BS), mineralized surface (MS/BS), and interlabel distances were measured at 20x 
magnification. Mineral apposition rate (MAR) was calculated from the interlabel distance and 
time of labels. Bone formation rate (BFR/BS) was determined by multiplying MS/BS by MAR.  
Additionally, 4 μm-thick sections were treated with von Kossa stain and tetrachrome 
counterstain to measure cancellous microarchitecture and osteoid (OS/BS) and osteoclast 
(Oc.S/BS) surfaces as a percent of total cancellous surface measured at 40x magnification. All 
nomenclature for cancellous histomorphometry follows standard usage (45). 
Dynamic cortical histomorphometry: Undemineralized left distal tibia were fixed in 
4% phosphate-buffered formalin for 24 hours and then serially dehydrated and embedded in 
methyl methacrylate. Cross sections of the bone closest to the mid-shaft were made on an IsoMet 
Low Speed Saw (Buehler, Lake Bluff, IL) approximately 100 µm thick. Cross sections were 
analyzed at 20x magnification using OsteoMeasure Analysis System, version 3.3 (OsteoMetrics, 
Inc., Atlanta, GA, USA) for MS/BS and MAR; bone formation rate was calculated as stipulated 
above. 
 41 
 
Immunohistochemistry:  Left distal femora were fixed in 4% phosphate-buffered 
formalin for 24 hours at 4○C and then decalcified in a sodium citrate/formic acid solution for 
approximately 14 days then stored in 70% ethanol. Sections were then further dehydrated in 
Thermo-Scientific STP 120 Spin Tissue Processor, paraffinized via a Thermo Shandon 
Histocenter 3 Embedding tool, sectioned to approximately 8 µm thickness, mounted on 
positively charged slides, and immunostained using an avidin-biotin method. Briefly, samples 
were rehydrated, peroxidase inactivated (3% H2O2/Methanol), permeabilized (0.5% Triton-X 
100 PBS), blocked with species-appropriate serum for 30 minutes at room temperature 
(Vectastain Elite ABC, Vector Laboratories, Burlingame, CA) and incubated overnight at 4○C 
with primary antibodies: polyclonal rabbit anti-rat TNF-α, (1:100, LifeSpan BioSciences, Inc, 
Seattle, WA), polyclonal rabbit anti-IL-6 (1:300, Abcam, Inc, Cambridge, MA), goat polycolonal 
anti-IL-10 (1:100, Santa Cruz Biotechnology, Dallas, TX), rabbit polyclonal anti-IGF-I (1:200, 
Abcam, Inc, Cambridge, MA), goat polyclonal anti-mouse RANKL (1:100, Santa Cruz 
Biotechnology, Dallas, TX), goat polyclonal anti-mouse OPG (1:100, Santa Cruz Biotechnology, 
Dallas, TX), polyclonal goal anti-mouse sclerostin (1:60, R&D Systems, Minneapolis, MN). On 
the subsequent day, sections were incubated at room temperature for 45 minutes with the 
appropriate species’ biotinylated anti-IgG secondary antibody according to manufacturer 
specifications.  Peroxidase development was performed with an enzyme substrate kit (DAB, 
Vector Laboratories). Counterstaining was conducted with 0.2% methyl green counterstain 
(Vector Laboratories) for 90 seconds; sections were subsequently dehydrated into organic phase 
and mounted with xylene-based mounting media (Polysciences, Warrington, PA). Negative 
controls for all antibodies were completed by omitting the primary antibody. Sections were 
analyzed by quantifying the proportion of all osteocytes staining positively for the protein in 
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three distinct bone compartments – cancellous bone (~500 microns from the growth plate, an 
area of approximately 4 mm2), metaphyseal cortical bone (~500 microns from growth plate, an 
area of approximately 2 mm2), and the cortical shaft (~100 microns distal to midshaft of bone, an 
area of approximately 2 mm2; Figure 1).  Negative controls (still containing methyl green stain) 
were used to quantify osteocyte density in the same bone compartments as listed above. 
  Statistical analyses: A t-test was completed between TNBS treated and Vehicle for 
each variable. Significance was determined at p<0.05. Effect size (partial eta-squared) was 
determined for values of p<0.05. All data is represented as mean ± standard deviation. 
Regression analysis was completed testing cancellous %RANKL+ osteocytes to cancellous 
osteoclast surface, %TNF-α+ osteocytes to %sclerostin+ osteocytes, and %sclerostin+ cancellous 
osteocytes to osteoid surface, %sclerostin+ cancellous osteocytes to cancellous osteoid surface 
and cancellous bone formation rate, and %sclerostin+ cortical shaft osteocytes to cortical bone 
formation rate. Statistics were completed using JMP Statistical Software (Cary, NC). 
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Figure 2.1: Bone regions and colon histopathology (A) Three regions of the distal femur analyzed via 
immunohistochemistry for percent-positive osteocytes and a representative image of regions of interest for analysis 
of immunohistochemistry of osteocytes. (B) Colon histopathology and representative images of colon from vehicle 
and TNBS. Histopathology score based on edema, crypt cell loss, cellularity, and intestinal epithelial cell damage 
was higher in TNBS versus vehicle (p = 0.049). *Indicates difference from vehicle. 
 
 
 
2.2 Results 
Animals:  After 28 days of either TNBS or Vehicle treatment, there were no 
differences in bodyweight between the groups (average weight = 345±19 grams, p=0.248).  
There were no animal losses throughout the experiment and all animals maintained normal 
eating and grooming behavior.  No modifications were made to the experimental protocol. 
Histopathology of the colon is elevated in TNBS treated animals: In TNBS treated 
animal colons, there were notable perforations in the mucosal layer as well as increased cellular 
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investiture in the lamina propria. A large and significant increase in the histopathology score (the 
sum of individual scored determinants - intestinal epithelial damage, crypt loss, cellularity, and 
edema) occurred in TNBS versus Vehicle treated animals (p<0.001; Figure 2.1). 
  TNBS resulted in slight declines in volumetric bone mineral density: Total vBMD at 
the proximal tibia metaphysis was 7% lower in TNBS compared to Vehicle treated animals, 
trending towards significance (p=0.058; Veh average = 414±29 mg/cm3, TNBS average = 
385±27 mg/cm3).  There were no differences in vBMD at the midshaft tibia (p=0.328; data not 
shown).   
Deficits in %BV/TV in proximal tibia metaphysis and 4th lumbar vertebrae (L4) are 
mediated by increased %Oc.S/BS and large declines in indices of bone formation.  Cancellous 
bone volume (BV/TV) was lower in TNBS compared to Vehicle treated animals in both the 
proximal tibia metaphysis and the 4th lumbar vertebrae (p=0.027, effect size=0.347 and p=0.026, 
effect size=0.35, respectively; Figure 2.2A). Except for a trend for a 21% increase in 4th lumbar 
vertebral trabecular separation in TNBS treated animals (p=0.058, proximal tibia p=0.121; 
Figure 2.2E), there were no other significant differences in trabecular thickness (proximal tibia 
p=0.180, L4 p=0.277; Figure 2.2D) or trabecular number (proximal tibia p=0.327, L4 p=0.282; 
Figure 2.2E) between the two groups. Cancellous osteoclast surface (Oc.S/BS) was higher in 
both the proximal tibia and 4th lumbar vertebrae in the TNBS-treated group (p=0.018, effect 
size=0.385 and p=0.004, effect size=0.511, respectively; Figure 2.2B). Osteoid surface (OS/BS) 
was lower in both the proximal tibia and 4th lumbar vertebrae in the TNBS treatment (p=0.001, 
effect size=0.630 and p=0.02, effect size=0.375, respectively; Figure 2.2C). In the proximal tibia 
metaphysis and the 4th lumbar vertebrae, mineralized surface (MS/BS) was lower in TNBS 
compared to Vehicle treatment (p<0.001, effect size=0.912 and p=0.006, effect size=0.809, 
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respectively; Figure 2.2G). In both bone compartments, mineral apposition rate (MAR) was also 
lower in TNBS (p=0.009, effect size=0.710 and p=0.018, effect size=0.709, respectively; Figure 
2.2H). Bone formation rate (BFR/BS) was lower in both cancellous bone sites in TNBS 
(p=0.002, effect size=0.828 and p=0.001, effect size=0.925, respectively; Figure 2.2I). 
 
 
 
Figure 2.2: Cancellous histomorphometry at the proximal tibia metaphysis and fourth lumbar vertebra (L4). (A) 
Cancellous bone volume was lower in TNBS in both the proximal tibia (p = 0.027) and L4 (p = 0.026). (B) 
Cancellous osteoclast surface was higher in TNBS at the proximal tibia (p = 0.018) and L4 (p = 0.004).  
Figure 2.2, continued. (C) Cancellous osteoid surface was lower in TNBS at the proximal tibia (p = 0.001) and 
L4 (p = 0.02). (D) No statistical differences in trabecular thickness.  
(E) No statistical differences in trabecular separation. (F) No statistical differences in trabecular number. (G) 
Mineralized surface was lower in TNBS at the proximal tibia (p < 0.001) and L4 (p = 0.006). (H) Mineral apposition 
rate was lower in TNBS at the proximal tibia (p = 0.009) and L4 (p = 0.018). (I) Cancellous bone formation rate was 
lower in TNBS at the proximal tibia (p = 0.002) and L4 (p = 0.001). (J) Representative images of static 
histomorphometry of the proximal tibia at ×400 magnification of a vehicle animal (right) and TNBS animal (left). 
*Indicates difference between TNBS and vehicle. 
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Midshaft tibia bone formation rate was lower in TNBS treated animals.  Mineralized 
surface was lower in the TNBS treated group (p=0.009, effect size=0.709; Figure 2.3C), but 
there were no differences between groups in mineral apposition rate (p=0.710; Figure 2.3D). 
Bone formation rate was approximately 35% lower in the TNBS treatment group (p=0.025, 
effect size=0.595; Figure 2.2A). 
Osteocyte density was lower in TNBS animals.  The total numbers of osteocytes 
quantified in the cancellous compartment of bone were lower in TNBS animals compared to 
Vehicle (p=0.005, effect size=0.527; Figure 2.4A).  Osteocyte density was also lower in TNBS 
treated animals in the metaphyseal cortical bone (p=0.003, effect size=0.612; Figure 2.4B) and 
the cortical shaft (p=0.036, effect size=0.340; Figure 2.4B). 
 
  
Figure 2.3: Cortical bone formation rate at the midshaft tibia. (A) Cortical bone formation rate was lower in TNBS 
compared to vehicle (p = 0.025). (B) Representative images of periosteal BFR at the midshaft tibia in a vehicle 
animal and TNBS animal at ×10 magnification. (C) Periosteal mineralized surface was lower in TNBS compared to 
vehicle (p = 0.009). (D) No statistical difference in mineral apposition rate at the midshaft tibia. *Indicates 
difference from vehicle. 
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Osteocyte prevalence of inflammatory markers were altered in TNBS animals: TNF-α: 
%TNF-α+ osteocytes were higher in TNBS-treated rats in both the cancellous bone and 
metaphyseal cortical bone (p=0.01; effect size=0.499 and p=0.046; effect size=0.341 
respectively; Figure 2.4C).  There were trending increases in the cortical shaft in TNBS-treated 
rats (p=0.062; Figure 2.4C). IL-6: %IL-6+ osteocytes were higher in TNBS-treated rats in the 
cancellous bone (p=0.005; effect size=0.548, and p=0.029; effect size=0.392, respectively; 
Figure 2.4D) and the metaphyseal cortical bone. There were no differences at the cortical shaft 
(p=0.134). IL-10: %IL-10+ osteocytes were not different between TNBS-treated rats and Vehicle 
in any bone compartment (cancellous p=0.620, metaphyseal p=0.808, shaft p=0.344; Figure 
2.4E). IGF-I: %IGF-I+ osteocytes were higher in TNBS-treated rats in the cancellous bone and 
the metaphyseal cortical bone (p=0.003; effect size=0.591 and p=0.013; effect size=0.471, 
respectively; Figure 2.4F). There were no differences at the cortical shaft (p=0.592). 
RANKL: %RANKL+ osteocytes were higher in the cancellous bone and the cortical shaft in 
TNBS-treated rats (p=0.011; effect size=0.455 and p=0.049; effect size=0.307, respectively; 
Figure 2.5A). There were no differences at the metaphyseal cortical bone between the groups 
(p=0.126). OPG: %OPG+ osteocytes were higher in the cancellous bone and the metaphyseal 
cortical bone in TNBS-treated rats (p=0.012; effect size=0.418 and p=0.035; effect size=0.320, 
respectively; Figure 2.5B).  There were no differences at the cortical shaft (p=0.644). Sclerostin: 
%Sclerostin+ osteocytes were higher in the cancellous bone (p<0.0001; effect size=0.782), the 
metaphyseal cortical bone (p=0.005; effect size=0.514), and the cortical shaft in TNBS treated 
animals (p=0.03; effect size=0.352; Figure 2.5E). 
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Figure 2.4: Immunohistochemical staining of osteocytes for density and percent positive TNF-α, IL-6, IL-10, and 
IGF-I. (A) Cancellous osteocyte density was lower in TNBS (p = 0.005). (B) Osteocyte density was lower in TNBS 
in both the metaphyseal cortical bone (p = 0.003) and the cortical shaft (p = 0.036). (C) %TNF-α+ osteocytes were 
higher in cancellous (p = 0.01) and metaphyseal cortical bone (p = 0.046) in TNBS compared to vehicle. (D) %IL-
6+ osteocytes were elevated in TNBS in the cancellous (p = 0.005) and metaphyseal cortical (p = 0.029) bone 
compartments. (E) %IL-10+osteocytes were not different between TNBS and vehicle. (F) %IGF-I+ osteocytes were 
higher in TNBS in both the cancellous (p = 0.003) and metaphyseal cortical bone (p = 0.013). *Indicates difference 
between TNBS and vehicle within specific bone compartment. 
 
 
The increase in %OPG+ osteocytes and %RANKL+ osteocytes statistically predicted 
the increase in osteoclast surface.  %RANKL+ cancellous osteocytes alone statistically predicted 
the increase cancellous osteoclast surface (R2=0.565, adjusted R2=511, p=0.012; Figure 2.5C). 
Additionally, the ratio of %OPG+ cancellous osteocytes to %RANKL+ cancellous osteocytes 
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statistically predicted cancellous osteoclast surface (R2=0.405, adjusted R2=0.339, p=0.035; 
Figure 2.5D). 
The increase in %TNF-α+ osteocytes statistically predicted the increased in 
%sclerostin+ osteocytes. %TNF-α+ cancellous osteocytes explained approximately 60% of the 
variability in %sclerostin+ cancellous osteocytes (R2=0.588, adjusted R2=0.546, p=0.004; Figure 
2.5F). 
The increase in %sclerostin+ osteocytes statistically predicted declines in bone 
formation. %Sclerostin+ cancellous osteocytes statistically predicted the decline in cancellous 
osteoid surface (R2=0.581, adjusted R2=0.539, p=0.004; Figure 2.5G) and cancellous bone 
formation rate (R2=0.674, adjusted R2=0.609, p=0.024). %Sclerostin+ cortical shaft osteocytes 
explained approximately 90% of the variability in cortical bone formation rate (R2=0.908, 
adjusted R2=0.890, p=0.001; Figure 2.5H). 
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Figure 2.5: Immunohistochemical staining of osteocytes for RANKL, OPG, and sclerostin with regression analyses. 
(A) %RANKL+osteocytes were higher in TNBS in the cancellous (p = 0.011) and cortical shaft (p = 0.049) bone 
compartments. (B) %OPG+ osteocytes were elevated in the cancellous (p = 0.012) and metaphyseal cortical bone in 
TNBS (p = 0.035). (C) Cancellous %RANKL+ osteocytes predicted the increase in cancellous osteoclast surface 
(R2 = 0.565, p = 0.012). (D) The ratio of %positive-osteocytes of OPG:RANKL predicted the increase in cancellous 
osteoclast surface (R2 = 0.405, p = 0.035). (E) %Sclerostin+ osteocytes were higher in TNBS in the cancellous 
(p < 0.0001), metaphyseal cortical (p = 0.005), and shaft (p = 0.03). (F) %TNF-α+ cancellous osteocytes predicted the 
increase in %sclerostin+ cancellous osteocytes (R2 = 0.588, p = 0.004). (G) %Sclerostin+ cancellous osteocytes 
predicted the decline in cancellous osteoid surface (R2 = 0.674, p = 0.024). (H) %Sclerostin+ cortical osteocytes 
predicted the decline in cortical bone formation rate (R2 = 0.908, p = 0.001). *Indicates difference between TNBS 
and vehicle within specific bone compartment. 
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2.3 Discussion 
 The findings of this study, first, provide confirmation in a rodent model of IBD that 
the magnitude of bone loss, increased bone resorption, and decreased bone formation are all 
associated with chronic inflammation initiated by the gastrointestinal pathology. Secondly, this 
study provides novel evidence of the role of osteocytes and osteocyte proteins in the systemic 
inflammation associated with IBD.   
Several other previously published studies have documented changes in bone mass and 
bone turnover due to IBD in rodent models similar to those seen in clinical patients (44, 45). This 
study corroborates these findings demonstrating loss of cancellous bone volume, increased bone 
resorption, and decreased bone formation in young male rats with an experimental model of IBD 
(Figure 2). These skeletal changes are concurrent with higher intestinal epithelial damage, crypt 
loss, increased cellularity, and edema in the colon of the IBD animals (Figure 2.1). Therefore, the 
primary inflammation and damage initiated in the gut appears capable of having a negative 
impact on multiple distant bone sites. The patterns of loss of cancellous bone volume and altered 
bone turnover were similar in the 4th lumbar vertebrae and the proximal tibia metaphysis. In 
patients with IBD, it is cancellous-rich bone sites like vertebral bone and the femoral neck that 
exhibit the most significant declines in bone mineral density and the greatest increase in fracture 
incidence (6, 13-16). In our study, the changes in the proximal tibia cancellous resorbing and 
forming surfaces were significantly altered (TNBS osteoclast surface was 76% higher than 
vehicle and osteoid surface was 60% lower than Vehicle; see Figure 2.2), while there were only 
tendencies towards lower volumetric bone mineral density (7% lower) in TNBS treated animals..  
Therefore, the bone loss measured in clinical studies via dual x-ray absorptiometry or computed 
tomography may under-estimate or not have adequate sensitivity to quantify the changes in bone 
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cell activity occurring in local bone sites. These patterns imply that inflammatory signals from 
the primary site of damage/inflammation in the gut are somehow transmitted to multiple distant 
bone sites. Additionally, in our study the rats only experienced four weeks of IBD and it is likely 
that greater loss of BMD would occur after an even longer period of IBD. Since IBD currently 
has no cure, should the alterations in bone turnover favoring bone resorption found in this animal 
model be maintained over longer periods of time, devastating losses of bone density and 
resistance to fracture could occur. 
 Pro-inflammatory cytokines, like TNF-α, are potent stimulators of osteoclastogenesis 
and osteoclast activity while also suppressing bone formation (22, 23). In a mouse model of IBD, 
elevated TNF-α gene expression was seen in the colon along with an elevated inflammation 
score (46). In previous work using the same experimental model of IBD, our group has shown 
rapid, large increases in TNF-α RNA expression in the mesenteric lymphatics (40). In this study, 
the %TNF-α-positive osteocytes in the cancellous and metaphyseal cortical bone were 
approximately 75% higher in TNBS rats than in vehicle-treated animals (Figure 4).  Likewise, 
IL-6, another pro-inflammatory cytokine, was approximately 60% higher in the osteocytes of 
TNBS treated animals in both metaphyseal bone compartments (Figure 2.4). These changes were 
coincident with increased osteoclast surface, decreased osteoid surface, and decreased bone 
formation rate in cancellous bone. In human IBD patients, serum IL-6 concentrations are 
significantly elevated in both children and adults (21, 24). Adding the serum from children with 
Crohn’s disease to fetal rat parietal bone cultures resulted in demineralization, while 
neutralization of IL-6 prevented changes in osteoblasts and morphology (21). Therefore, it 
appears that serum IL-6 plays a significant role in the altered bone turnover in IBD. Since IL-6 is 
also a product of osteocytes (35, 36), it is possible that the local inflammatory state in bone is 
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dependent on direct osteocyte contributions to IL-6 and not merely responding to systemic 
signals. In our study, the osteocyte prevalence of IL-10 was not different in osteocytes in TNBS-
treated versus Vehicle-treated animals (Figure 2.4). While the role of IL-10 in IBD in humans 
remains poorly understood and equivocal in the pathology of IBD, the osteocyte IL-10 we 
observed was not elevated like the increased serum IL-10 concentrations in patients with IBD 
(26, 27). Clinical studies have been inconsistent regarding serum IL-10 levels, with some 
patients showing elevated IL-10 (presumably as a compensatory mechanism to gut 
inflammation), but other studies have shown no elevation in IBD patients compared to healthy 
populations (47). It is known IL-10 -/- mice develop systemic osteopenia, and that the degree of 
osteopenia is more severe in IL10 -/- mice with spontaneous colitis than without, supporting a 
critical role of inflammation beyond IL-10 mediated mechanisms (48). Furthermore IL-10’s role 
in influencing bone turnover or resorption is equivocal, with the interaction of IL-10 and its 
impact on osteocyte biology unknown (48). Therefore in the local bone tissue, there does not 
appear to be a compensatory, anti-inflammatory response via IL-10 mechanisms but this does not 
exclude other members of the IL-10 family such as the IL-20 subfamily, which will be the 
subject of future studies (47, 48). Taken together, these data suggest an established pro-
inflammatory state in bone, specifically in osteocytes, after four weeks of IBD in this rodent 
model. 
Alterations in RANKL and OPG have also been implicated as playing roles in elevated 
bone resorption in IBD due to altered serum concentrations in patients, with high OPG:RANKL 
ratios favoring osteoclast formation (4, 6, 32-34). Studies of colonic explant cultures have 
identified inflamed colon tissue as source of OPG (34); however, RANKL and OPG are also 
produced by osteocytes and osteoblasts, hence one of our goals was to examine osteocyte 
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RANKL and OPG in these IBD animals. Percent-positive RANKL and OPG osteocytes were 
indeed higher in TNBS compared to Vehicle-treated rats (Figure 2.5). Using a regression model, 
%RANKL+ osteocytes explained approximately 57% of the variability in the increase in 
cancellous osteoclast surface (R2=0.565) and the ratio of OPG to RANKL positive osteocytes 
explained approximately 40% of the variability in the increase in osteoclast surface (R2=0.405). 
The direction of these changes in osteocyte prevalence of RANKL and OPG is similar to that 
seen in circulating serum concentrations in human IBD patients. The increased RANKL is likely 
due to increased inflammation, particularly from TNF-α, as TNF-α cooperates with RANKL in 
osteoclast formation (49-50). It has been hypothesized that the increase in OPG is either a 
compensatory response to increased bone resorption or that it is simply a response to the 
inflammatory state (33). In addition, cell culture studies have found OPG mRNA in osteoblasts is 
increased by TNF-α (51) indicating it, too, may be directly influenced by an increased pro-
inflammatory state.   
Inflammatory bone loss is not only characterized by an increase in bone resorption, but 
also a decrease in bone formation (20).  Both TNF-α and IL-6 have been implicated in this 
decline in bone formation via suppression of osteoblasts (21, 22). In this study, we investigated 
two other osteocyte proteins that directly regulate osteoblast function and bone formation.  IGF-I 
is a potent stimulator of bone formation (52) and TNF-α suppresses its actions in osteoblasts 
(22). Osteocyte-derived IGF-I plays a role in the adaptation of bone to mechanical loading (40, 
41), but how it is altered with systemic inflammation has not been explored. We hypothesized 
that osteocyte IGF-I would decrease in IBD rats, based on documented declines observed in 
serum IGF-I concentrations in IBD patients (24, 53). Contrary to our hypothesis, we observed an 
increase in osteocyte-specific IGF-I in IBD animals (Figure 2.4). This increase in %IGF-I+ 
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osteocytes could represent a local mechanism compensating for declines in systemic IGF-I by 
local secretions of this potent anabolic factor; however, the elevated IGF-I levels in osteocytes 
did not rescue the observed decline in bone formation in these IBD rats. Future studies will 
address whether circulating concentrations of IGF-I are lower in this rodent model of IBD 
similar to what is seen in human patients.  
 Another osteocyte protein that regulates bone formation is sclerostin, which inhibits the 
Wnt/β-catenin signaling pathway, thereby suppressing osteoblast activity (54). TNF-α is a 
transcriptional activator of sclerostin; in a recently published study, diet-induced obesity in mice 
resulted in elevated TNF-α and sclerostin in bone (36). In our study, we found elevated osteocyte 
sclerostin prevalence in all bone compartments of the distal femur (Figure 2.5). Nearly 60% of 
the increase in sclerostin was statistically predicted by increases in osteocyte TNF-α via 
regression analysis. In turn, %sclerostin+ osteocytes closely predicted the declines in cancellous 
osteoid surface and cancellous and cortical bone formation rate. Therefore, we demonstrate that 
an increased pro-inflammatory state (i.e. increased osteocyte TNF-α) was strongly associated 
with elevated osteocyte sclerostin and decreased bone formation activity.    
Interestingly, in this study the largest significant changes in %positive osteocyte proteins 
were in the metaphyseal bone – primarily the cancellous compartment followed by the 
metaphyseal cortical bone. Except for sclerostin and RANKL, the other proteins that did change 
in the metaphyseal bone were not significantly altered in the cortical shaft of the bone. This 
corresponds with the clinical evidence of increased bone loss and fracture risk in cancellous-rich 
bone sites like vertebral bone. Additionally, we found lower osteocyte density in all 
compartments of the bone in IBD animals (Figure 2.4). This effect was not localized solely to the 
cancellous bone compartment but to both cancellous and cortical compartments. IBD animals 
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had fewer osteocytes in all compartments, but of those osteocytes still present (particularly in the 
cancellous bone), there was a higher prevalence of osteocytes positive for all proteins measured 
in this study except IL-10. The lower number of osteocytes in IBD animals may suggest 
increased apoptosis, which warrants further study. 
In conclusion, we found that four weeks of inflammatory bowel disease in young male 
rats resulted in increased bone resorption, decreased bone formation, and loss of cancellous bone 
volume. Distant inflammatory changes initiated in the gut in this animal model of IBD resulted 
in increased prevalence in the distal femur osteocytes positive for TNF-α, IL-6, RANKL, OPG, 
IGF-I, and sclerostin. The altered prevalence of these factors was seen as a local increase in the 
bone inflammatory state coincident with increased bone resorption and decreased bone formation 
in all bone compartments tested. Osteocytes, often considered the primary cell type regulating 
bone formation/resorption, were impacted by the gut inflammation caused by IBD. The pathways 
by which the signals initiated in the gut alter the systemic immune response and produce the 
serum signals that in turn affect bone at multiple distant sites are not yet understood. However, 
these data suggest that bone cells are not simply passively responding to the circulating 
inflammatory signals from the gut, but that the osteocyte response plays a key regulatory role in 
the development of IBD-induced bone loss. 
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3. A MODERATELY ELEVATED SOY PROTEIN DIET MITIGATES 
INFLAMMATORY CHANGES IN CANCELLOUS BONE TURNOVER DURING 
CHROINC TNBS-INDUCED INFLAMMATORY BOWEL DISEASE 
The influence of diet on the course of inflammatory bowel disease is poorly understood. 
Food antigens are the second most common antigen present in the intestinal lumen second only 
to bacterial antigens; therefore, nutritional factors could play important roles in the development 
of gut inflammation (1). However, this area of research remains inconclusive. Some evidence 
links high sugar intake, high animal protein and cholesterol intake with the development of IBD 
(2-5) and high consumption of vegetables with lower risk of developing IBD (5). The results of 
the few clinical trials for nutritional interventions during active IBD, like low sugar diets, have 
been inconsequential (1, 2). Despite the lack of evidence for nutritional influence on IBD, 
determining a specific diet or nutrient that could produce anti-inflammatory benefits to protect 
gut and bone health would improve clinical care and quality of life in patients. 
 While there are some links between high animal protein consumption and the 
development of gut inflammation, there is some preliminary evidence demonstrating that plant-
based soy protein may actually exert anti-inflammatory effects. In postmenopausal women, soy 
protein intake decreases circulating C reactive protein levels, a non-specific measure of 
inflammation, as well as the pro-inflammatory marker, interleukin-18 (6). Soy protein 
consumption decreases macrophage infiltration in an animal model of polycystic kidney disease 
(7). Additionally, the severity of atherosclerotic lesions is lessened with a soy protein diet in 
apolipoprotein E-deficient mice potentially through inhibiting monocyte chemoattractant protein-
1, part of the inflammatory response (8). Two animal models of IBD have examined the use of 
soy protein. In dextran sodium sulfate-induced colitis in piglets, soy-derived di- and tri-peptides 
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attenuate colonic expression of pro-inflammatory cytokines and inflammatory gut changes (9). In 
mice with dextran sodium sulfate colitis, consumption of soy protein, but not casein or probiotic 
supplementation, decreases gut inflammatory scores and colonic gene expression of TNFα (10). 
These data indicate that soy protein may exert unique anti-inflammatory effects in the gut and 
beneficially impact the course of inflammatory conditions like IBD. These studies all only 
examine the impact of soy on acute gut inflammation and do not address distant tissues affected 
by IBD like bone. 
 With regards to bone health, protein consumption has a controversial history due to 
concerns of excess protein creating a negative calcium balance in the body; however, a 
controlled study with stable isotope tracing in healthy young females demonstrated no negative 
alterations in bone turnover with high protein diets (11). Additionally, large epidemiological 
studies demonstrate the opposite of the concern with low protein intake associated with increased 
bone loss in the elderly (12). A meta-analysis also demonstrates slight improvements in lumbar 
spine BMD with protein supplementation (13). Importantly, there is also no evidence of a 
detrimental effect of protein consumption on fracture incidence (13). In overweight participants 
in a weight loss trial, protein supplementation mitigates the decline in bone mass seen due to 
energy restriction (14). Whether a moderately elevated protein diet would attenuate bone loss in 
chronic inflammation is unknown. A diet high in soy isoflavones, but without elevated protein 
consumption, mitigates lumbar spine bone loss in perimenopausal women (15). In young male 
rats with a high protein diet, soy protein increases cancellous and cortical volumetric bone 
mineral density (16). Whether soy protein can mitigate inflammatory bone loss has not been 
examined. 
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 The purpose of this current project is to examine the impact of a moderately elevated 
soy protein diet during chronic gut inflammation in an animal model of IBD. We hypothesized 
that a moderately elevated soy protein diet would improve gut pathology and mitigate the 
inflammatory status of bone compared to a standard rodent control diet with protein from casein, 
a primary protein in dairy milk. Specifically, we hypothesized our dietary intervention would 
mitigate gut pathology and decrease osteocyte TNF-α, IL-6, RANKL, OPG, and sclerostin. 
These changes would correlate with an increase in bone formation rate and a decrease in 
osteoclast surface, an indicator of resorptive activity. Additionally, we hypothesized that 
osteocyte IGF-I would increase with the dietary protein intervention concurrent with increased 
bone formation rate. 
3.1 Materials and Methods 
Animals: Thirty-two male Sprague-Dawley rats (1.5 months old) were ordered from 
Envigo (Houston, Texas) and singly housed in an institutionally approved animal facility with 12 
hour light dark cycles.  Animals were allowed approximately four days to acclimate to the 
facility before being switched from standard rodent chow (Teklad 2018, Envigo) to the purified 
AIN93G chow (Research Diets, Inc., New Brunswick, NJ). Animals were allowed free access to 
food and water. Following the one week acclimation to the diet, animals were randomly divided 
into four different groups (n=8/group): Vehicle (Veh), Vehicle with soy protein (Veh+Pro), IBD 
induced via 2,4,6-trinitrobenzenesulfonic acid (TNBS), and IBD with soy protein (TNBS+Pro). 
Gut inflammation was induced by rectal instillations of 1 uL/gram body weight, of 2,4,6-
trinitrobenzenesulfonic acid (TNBS; 30 mg/kg, Sigma Aldrich, St Louis, MO) in 30% 
ethanol:DiH2O solutions, as previously described (17, 18). The 30% ethanol was used to disrupt 
the mucosal barrier while the haptenizing agent, TNBS, stimulated an immune response leading 
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to gut inflammation. On days 1, 7, 14, 21, and 26 non-fasted rats were anesthetized via inhaled 
isoflurane with a precision vaporizer and given enemas with either vehicle or TNBS using an 18-
gauge catheter with a blunted end inserted 7.5 cm into the rectum. The anus was held closed for 
5 minutes after instillation to control the contact of the enema solution with the colon, after 
which animals were allowed to recover from anesthesia. Rectal instillations began at 2 months of 
age and continued for up to four weeks. Fluorochrome calcein labels (Sigma Aldrich, St Louis, 
MO) were injected intraperitoneally eight and three days prior to termination to label mineralized 
surfaces on bone. Animal health was monitored daily and food intake and bodyweight were 
measured several times per week for the entire experimental period. After four weeks of TNBS 
or Veh treatment, rats were anesthetized via inhaled vaporized isoflurane, euthanized via 
thoracotomy, and tissues were collected. All animal procedures were approved by the Texas 
A&M Institutional Animal Use and Care Committee and conform to the NIH Guide for the Care 
and Use of Laboratory Animals. 
Diets: Beginning on the first day of rectal instillations, all Pro animals were switched 
from the AIN93G diet formulated with 20% of the kilocalories coming from casein to a 
specialized diet based on the AIN93G with 35% of the kilocalories coming from soy protein 
(Research Diets, Inc). Diet specifications are detailed in Table 3.1 and Table 3.2. Rats were kept 
on the Pro diet continuously for the remainder of the study. Food intake was monitored 
throughout the entire study. 
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Table 3.1: Percent kilocalories of macronutrients in the control and moderately elevated soy diet. 
 Control Diet %kcal Soy Protein Diet %kcal 
Protein 20 35 
Carbohydrate 64 49 
Fat 16 16 
Total 100 100 
 
 
 
Table 3.2: Control and moderately elevated soy protein diet composition. Information provided by Research Diets, 
Inc. 
 
Ingredient Control Diet Soy Protein Diet 
Casein 200 gm 0 
Soy protein 0 345 gm 
DL-methionine 0 5 gm 
L-cystine 3 gm 0  
Corn starch 397 gm 250 gm 
Maltodextrin 10 132 gm 132 gm 
Sucrose 100 gm 100 gm 
Cellulose 50 gm 50 gm 
Soybean oil 70 gm 70 gm 
t-Butylhydroquinone 0.014 gm 0.014 gm 
Mineral mix 35 gm 35 gm 
Vitamin mix 10 gm 10 gm 
Choline Bitartrate 2.5 gm 2.5 gm 
Total 1000 gm 1000 gm 
 
 
Tissue processing and histological analysis: Whole length colons were removed, 
processed, and were scored from H&E stained sections based on epithelial structure, crypt 
structure, cellularity, and edema. Scores were adjusted to account for area of tissue affected. All 
scores were conducted blindly.  
Dynamic and Static Histomorphometry: Undemineralized right proximal tibia and 
fourth lumbar vertebrae (L4) were fixed in 4% phosphate buffered formalin and then subjected to 
serial dehydration and embedded in methyl methacrylate (J.T. Baker, VWR, Radnor, PA). Serial 
frontal sections at 8 µm thickness were left unstained for analysis of fluorochrome labels for 
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dynamic histomorphometry. The histomorphometric analyses were performed using 
OsteoMeasure Analysis System, version 3.3 (OsteoMetrics, Inc., Atlanta, GA, USA). For the 
proximal tibia, a defined region of interest was established approximately 500 μm from the 
growth plate and within the endocortical edges encompassing approximately 8 mm2 at 20x 
magnification. Total bone surface (BS), single-labeled surface (sLS/BS), double-labeled surface 
(dLS/BS), mineralized surface (MS/BS), and inter-label distances were measured at 20x 
magnification. Mineral apposition rate (MAR) was calculated from the time lapsed between label 
deliveries. Bone formation rate (BFR/BS) was determined by multiplying MS/BS by MAR.  
Additionally, 4 μm-thick sections were treated with von Kossa stain and tetrachrome 
counterstain to measure cancellous microarchitecture and osteoid (OS/BS) and osteoclast 
(Oc.S/BS) surfaces as a percent of total cancellous surface measured at 40x magnification. All 
nomenclature for cancellous histomorphometry follows standard usage (19). 
Immunohistochemistry of Osteocyte Proteins: Left distal femora were fixed in 4% 
phosphate-buffered formalin for 24 hours at 4○C and then decalcified in a sodium citrate/formic 
acid solution for approximately 14 days then stored in 70% ethanol. Sections were then further 
dehydrated in Thermo-Scientific STP 120 Spin Tissue Processor, paraffinized via a Thermo 
Shandon Histocenter 3 Embedding tool, sectioned to approximately 8 µm thickness, mounted on 
positively charged slides, and immunostained using an avidin-biotin method. Briefly, samples 
were rehydrated, peroxidase inactivated (3% H2O2/Methanol), permeabilized (0.5% Triton-X 
100 PBS), blocked with species-appropriate serum for 30 minutes at room temperature 
(Vectastain Elite ABC, Vector Laboratories, Burlingame, CA) and incubated overnight at 4○C 
with primary antibodies: polyclonal rabbit anti-rat TNF-α, (LifeSpan BioSciences, Inc, Seattle, 
WA), polyclonal rabbit anti-IL-6 (Abcam, Cambridge, MA), polyclonal rabbit anti-IL-10 
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(Abcam), polycloncal rabbit anti-IL-4 (Abcam), polyclonal rabbit anti-annexin V (Abcam), 
polyclonal goat anti-mouse sclerostin (R&D Systems, Minneapolis, MN), polyclonal rabbit anti-
RANKL (Abcam), and polyclonal rabbit anti-OPG (Biorbyt, San Francisco, CA). On the 
subsequent day, sections were incubated at room temperature for 45 minutes with the appropriate 
species’ biotinylated anti-IgG secondary antibody according to manufacturer specifications.  
Peroxidase development was performed with an enzyme substrate kit (DAB, Vector 
Laboratories). Counterstaining was conducted with 0.2% methyl green counterstain (Vector 
Laboratories) for 90 seconds; sections were subsequently dehydrated into organic phase and 
mounted with xylene-based mounting media (Polysciences, Warrington, PA). Negative controls 
for all antibodies were completed by omitting the primary antibody. Sections were analyzed by 
quantifying the proportion of all osteocytes staining positively for the protein in the cancellous 
bone (~500 microns from the growth plate, an area of approximately 4 mm2). Previous data 
demonstrated that the cancellous bone region was the bone compartment with osteocytes most 
responsive to inflammation due to IBD. 
Statistical analyses: All data were tested for homogeneity and analyzed using a 2x2 
factorial ANOVA to determine main effects of diet and TNBS.  If a diet-by-TNBS interaction 
was present (p<0.05), all-groups analysis was completed. If the main effects were significant 
(p<0.05), a Duncan post-hoc test was used to determine differences between groups. Statistical 
analyses were completed on SPSS (IBM; Armonk, NY). All data are represented as mean ± 
standard deviation.   
3.2 Results 
All animals maintained bodyweight and consistent food intake across the course of the 
study regardless of treatment or diet. There were no statistical differences in bodyweight 
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between any groups at any time point in the study. Additionally, food intake was not different 
due to treatment or diet (Table 3.3). 
 
 
Table 3.3: Average daily food intake and final bodyweights. No groups were statistically different from each other at 
any time point. 
 
Measure Veh Veh+Pro TNBS TNBS+Pro 
Average daily 
food intake 
17.16±1.2 16.3±2.1 17.3±1.6 16.4±1.3 
Final bodyweight 355±17 351±17 348±30 333±14 
 
 
The moderately elevated soy protein diet mitigated gut damage and inflammation 
during chronic TNBS. There were significant main effects on colon pathology scores for 
treatment, diet, and a significant treatment-by-diet interaction (p<0.0001 for all).  This 
aggregated score for TNBS-treated rats was higher than those for all other groups, with 
TNBS+Pro values no different from both Veh groups (Figure 3.1). 
 
 
Figure 3.1: Colon histopathology. TNBS was higher than all other groups (p < 0.0001).  
*Indicates difference from all other groups. 
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The soy protein diet mitigated the increase in osteoclast surface seen in TNBS. At both 
the proximal tibia and L4, there was a main effect of TNBS (p=0.001 for both) and a main effect 
of diet (p=0.026, p=0.039, respectively). There was a significant interaction effect only at the 
proximal tibia (p=0.04). For both proximal tibia and L4, the TNBS group had the highest 
osteoclast surface of all groups. TNBS+Pro animals were no different than both vehicle-treated 
rats at both sites (Figure 3.2A). 
The soy protein diet increased bone formation rate in both TNBS and Veh treated 
animals. For bone formation rate, there were significant main effects of treatment and diet at 
both the proximal tibia and L4 (p<0.0001 for all) with a significant interaction effect between 
treatment and diet at the proximal tibia (p<0.0001). At the proximal tibia, the TNBS group BFR 
values were lower than all other groups while the protein diet increased BFR. At L4, TNBS 
animals had the lowest BFR with TNBS+Pro animals no different from vehicle-treated (Figure 
3.3A). At the proximal tibia there were significant main effects for both treatment and diet 
(p<0.0001 for both) in MS/BS and main effects for treatment and diet (p=0.003, p=0.004) for 
MAR. There were non-significant interaction effects for both MS/BS (p=0.067) and MAR 
(p=0.077) at the proximal tibia. At the proximal tibia, both TNBS groups had lower MS/BS than 
both Vehicle groups (Figure 3.3B). For MAR, the TNBS group was lower than all other groups. 
At L4, there were main effects for both treatment and diet (p<0.0001 for both) for MS/BS, but 
only a main effect for diet on MAR (p=0.009). MS/BS was lowest in the TNBS group with the 
TNBS+Pro group no different than vehicle-treated. For MAR, the TNBS group was lower than 
both soy protein groups with the vehicle group no different from any other group (Figure 3.3C). 
In osteoid surface measured via static histomorphometry, similar changes were seen as in MS/BS 
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with both TNBS groups lower than Veh groups in the proximal tibia and TNBS lower than all 
other groups in L4 (Figure 3.2B).   
 
 
Figure 3.2: Histomorphometric analysis of the proximal tibia and 4th lumbar vertebrae. (A) Osteoclast surfaces were 
higher in TNBS in both bone sites. TNBS+Pro was not different than vehicle groups. (B) Osteoid surface was lower 
in both TNBS groups at the proximal tibia, but only lower in TNBS in L4. *Indicates difference from all other 
groups. Bars not sharing the same letter are statistically different. 
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Figure 3.3: Dynamic histomorphometry of the proximal tibia and 4th lumbar vertebrae. (A) Cancellous BFR at the 
proximal tibia was lowest in TNBS and elevated due to Pro. At L4, TNBS+Pro increased BFR to Veh levels. (B) 
Pro had no effect on MS/BS at the proximal tibia, but increased MS/BS at L4. (C) Mineral apposition rate was lower 
in TNBS at the proximal tibia, but no different from Veh in TNBS+Pro. At L4, MAR was increased due to Pro. 
*Indicates difference from all other groups. Bars not sharing the same letter are statistically different. 
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Pro-inflammatory osteocyte proteins were reduced due to soy protein diet in TNBS 
animals.  TNF-α: There were significant main effects of both TNBS and diet (p<0.0001) on 
%TNF-α+ osteocytes as well as a significant interaction effect (p=0.028). The TNBS group was 
higher than all other groups with the TNBS+Pro group no different than the Veh group (Figure 
3.4A). IL-6: For %IL-6+ osteocytes there was a main effect of treatment (p=0.001) and diet 
(p=0.01), but no interaction effect (p=0.882). The TNBS group had the highest IL-6+ osteocytes 
with TNBS+Pro no different from either the TNBS alone group or the Veh+Pro group (Figure 
3.4B). IL-4: There was a main effect of TNBS treatment (p<0.0001), a main effect of diet 
(p=0.025), and an interaction effect (p=0.033) for IL-4+ osteocytes. The TNBS group had lower 
osteocyte IL-4 than all other groups (Figure 3.4C). IL-10: There was only a main effect of diet 
on IL-10+ osteocytes (p=0.002) and no effect of treatment (p=0.934) or an interaction (p=0.131). 
The TNBS group had the highest IL-10 with the Veh group no different from either TNBS or 
Veh+Pro groups. The TNBS+Pro group had the lowest IL-10+ osteocytes (Figure 3.4D). 
RANKL: There was a significant main effect of treatment (p<0.0001) and a significant 
interaction effect (p=0.004), but no effect of diet on RANKL+ osteocytes (p=0.120). The TNBS 
group had the highest levels of RANKL, significantly higher than all other groups (Figure 3.5A). 
OPG: Main effects for treatment and treatment-by-diet were present in OPG+ osteocytes 
(p<0.0001, p=0.004, respectively), but no effect of diet (p=0.061). The TNBS group had the 
highest OPG followed by TNBS+Pro. The Veh+Pro was no different from either the TNBS+Pro 
or Veh groups (Figure 3.5B). IGF-I: For IGF-I+ osteocytes, there was only a significant 
interaction effect (p=0.01). There were no effects of treatment (p=0.463) or diet (p=0.528). The 
TNBS group had the highest osteocyte IGF-I with TNBS+Pro no different than Veh (Figure 
3.5C). Sclerostin: While there was a non-significant interaction effect in sclerostin+ osteocytes 
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(p=0.077), there were main effects of both treatment (p=0.038) and diet (p=0.018). The TNBS 
group had the highest osteocyte sclerostin of all groups (Figure 3.5D). Annexin V: There was a 
main effect of annexin V-positive osteocytes for treatment (p=0.048) and diet (p=0.001) and a 
significant interaction effect (p=0.011). The TNBS group had the highest Annexin V positive 
osteocytes of all groups. TNBS+Pro was no different from either vehicle-treated group (Figure 
3.5E). 
 
 
Figure 3.4: Immunohistochemistry of the distal femur cancellous osteocytes for inflammation-related factors. (A) 
TNF-α-positive osteocytes were highest in TNBS. TNBS+Pro was no different than Veh. (B) IL-6-positive 
osteocytes were highest in TNBS and lowered due to Pro, but TNBS+Pro was not different from either TNBS or 
Veh. (C) IL-4-positive osteocytes were lower in TNBS than all other groups. TNBS+Pro was not different from 
Veh. (D) IL-10-positive osteocytes were no different between TNBS and Veh, but lower due to Pro. *Indicates 
difference from all other groups. Bars not sharing the same letter are statistically different. 
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Figure 3.5: Immunohistochemistry of the distal femur cancellous osteocytes. (A) RANKL-positive osteocytes were 
highest in TNBS. TNBS+Pro was no different than Veh. (B) OPG-positive osteocytes were highest in TNBS. 
TNBS+Pro was not statistically different from TNBS or Veh. (C) IGF-I-positive osteocytes were elevated due to 
TNBS. TNBS+Pro was no different from Veh. (D) Sclerostin-positive osteocytes were higher in TNBS and 
TNBS+Pro was no different from Veh. (E) Annexin V-positive osteocytes were higher in TNBS, but no different 
from Veh in TNBS+Pro. (F) Representative image of immunohistochemistry of cancellous osteocytes.*Indicates 
difference from all other groups. Bars not sharing the same letter are statistically different. 
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3.3 Discussion 
 The primary finding of this study is that a moderately elevated soy protein diet 
successfully mitigated gut inflammation and beneficially altered bone turnover in an animal 
model of chronic inflammatory bowel disease. Secondly, this study demonstrates that osteocyte 
proteins are altered with increased dietary intake of soy protein coincident with positive changes 
in bone turnover. These results suggest a potential regulatory role of osteocytes in inflammatory 
bone loss whereby osteocytes release proteins to signal to osteoblasts and osteoclasts.   
 The beneficial effects of soy protein on gut inflammation have been demonstrated 
previously in animal models. In piglets with induced IBD via dextran sodium sulfate (DSS), soy 
protein isolate supplementation, while it did not fully alleviate the symptoms associated with gut 
inflammation, macroscopic analysis of the colons reveal the soy protein isolate treatment 
reduced colon inflammation and gut permeability (9). Similarly, DSS mice on a diet with 20% 
caloric intake from soy protein had a decrease in colon shortening and a reduction in colon 
inflammation, while diets consisting of 20% protein from casein and whey had no beneficial 
effect on gut inflammation (10). Both these studies examined acute outcomes with only 4-5 days 
of DSS administration to induce gut inflammation. In our study, we examined chronic gut 
inflammation after 28 days of TNBS-induced IBD. Our rats on a diet with 35% caloric content 
from soy protein had colon histopathology scores no different from vehicle-treated rats 
indicating successful mitigation of gut inflammation due to the moderately elevated soy protein 
diet. Our data along with the previous studies utilizing soy protein highlight the beneficial impact 
of soy protein on gut parameters during acute and chronic gut inflammation.  
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 In the current study, we found similar increases in osteoclast surface and decreases in 
osteoid surface and bone formation rate due to chronic IBD in our young male rats to those 
previously reported (17). The moderately elevated soy protein diet in TNBS rats reduced 
osteoclast surface at both the proximal tibia and L4 by 26-36% compared to that value observed 
in TNBS rats on normal rodent chow resulting in osteoclast surface values no different from 
those of vehicle-treated rats. In osteoid surface, there was no beneficial effect of soy protein 
during TNBS in the proximal tibia, but in the lumbar vertebrae the diet increased osteoid surface 
by ~110% compared to TNBS alone; however, this was still ~20% lower than in vehicle-treated. 
Dynamic histomorphometry at both sites revealed similar patterns in mineralized surface, with 
no differences between TNBS and TNBS+Pro at the proximal tibia, but elevated mineralized 
surface in TNBS+Pro compared to TNBS at L4. Despite minimal changes in mineralized surface 
(MS/BS) and osteoid surface at the proximal tibia due to the dietary intervention in TNBS 
animals, bone formation rate was approximately 50% higher in both soy protein groups versus 
the control diet comparators. This increase in BFR at the proximal tibia was due largely to 
increased mineral apposition rate (MAR). In L4, both MS/BS and MAR were elevated due to the 
soy protein intervention. This indicates a site-specific effect of soy protein on osteoblasts with 
potentially greater recruitment of osteoblast teams at the L4 cancellous bone, but greater activity 
of osteoblast teams in both long bone and vertebral cancellous compartments. Regardless of the 
exact mechanisms, the moderately elevated soy protein diet did mitigate the increased osteoclasts 
due to TNBS and increased bone formation rate even during chronic gut inflammation. 
 The inflammatory insult in the gut during chronic IBD leads to an increase in Th1 
cytokines such as TNF-α and IL-6. Previously, we discovered these pro-inflammatory cytokines 
are elevated in osteocytes in bone during chronic IBD correlating with increased osteoclast 
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surface and decreased BFR (17). We hypothesized that mitigation of the inflammation in the gut 
would result in mitigation of the bone inflammatory changes as well. The two previously 
published studies examining soy protein’s impact on acute gut inflammation in animal models 
demonstrate that soy protein attenuates colonic expression of TNF-α, corresponding with 
decreased inflammatory scores (9, 10). Therefore, these studies concluded that soy protein can 
act as an anti-inflammatory agent; however, neither of these studies examined bone outcomes. In 
our study, we found nearly a three-fold decrease in TNF-α-positive osteocytes in TNBS+Pro 
animals compared to those animals TNBS alone resulting in no osteocyte TNF-α difference 
between TNBS+Pro rats and vehicle-treated rats. Osteocyte IL-6 was 18% lower in TNBS+Pro 
rats compared to the TNBS group alone. These reductions in osteocytes positive for pro-
inflammatory cytokines correspond with the reduced osteoclast surface in IBD animals fed the 
moderately elevated soy protein diet. Also, since TNF-α suppress osteoblast formation and 
activity (20), the decrease in TNF-α in bone likely supports the increase in BFR. 
 Th2 cytokines, like interleukin-10, are often considered “anti-inflammatory” and have 
a more equivocal role in IBD pathology, as discussed in our previous work (17) in which we 
found no alterations in IL-10-positive osteocytes in IBD rats after four weeks of treatment. We 
confirmed that finding in this current study but did, however, find a significant effect of our soy 
protein diet on decreasing IL-10-positive osteocytes in rats. In cell culture models, IL-10 inhibits 
osteoclasts (21, 22), but the functional role of osteocyte IL-10 is unknown. What the decreased 
osteocyte IL-10 with the soy protein intervention indicates is uncertain since osteoclast surface is 
also depressed with moderately elevated soy protein. Another Th2 cytokine, interleukin-4 (IL-4), 
we discovered to be decreased in TNBS-treated animals, but restored back to vehicle levels with 
the soy protein diet. IL-4, similar to IL-10, has implicated actions in inhibiting RANKL and 
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preventing osteoclastogenesis (23, 24). The role of osteocyte IL-4 is also unknown at this time. 
In summary, our data indicate that the moderately elevated soy protein diet alters Th2 cytokines 
as well as Th1, but further work must be done to define the functional roles these Th2 cytokines 
play in osteocytes, osteoclasts, and osteoblasts in the context of inflammation. 
 RANKL and OPG, regulators of osteoclast formation, are altered in the serum of IBD 
patients (25) and in osteocytes of IBD rats (17). We found osteocyte-specific RANKL and OPG 
to be 3- to 4-fold higher, respectively, in the TNBS group as compared to those in vehicle-treated 
rats. The soy protein intervention reduced the percentage of RANKL-positive osteocytes by 43% 
and OPG-positive osteocytes by 41% in TNBS animals. These changes corresponded with 
decreased osteoclast surface at both the proximal tibia and L4 in the TNBS+Pro group. Since 
RANKL and OPG are regulated in part by TNF-α (26, 27), the decrease in TNF-α seen with the 
soy protein diet likely contributed to the decrease in both RANKL and OPG. Additionally, 
another osteocyte protein, sclerostin, is upregulated by TNF-α (28) and elevated in IBD (17). The 
soy protein intervention reduced osteocyte sclerostin by 31% as compared to TNBS rats on 
normal diet and to the same level as observed in vehicle-treated rats. This decline in sclerostin, a 
negative regulator of osteoblasts, corresponded with increased bone formation rate. Finally, 
TNF-α can also induce apoptosis of osteocytes (29) which, in turn, can lead to increased 
recruitment of osteoclasts to that area to resorb bone (30). We found annexin V, a marker of 
apoptosis, to be more prevalent in osteocytes due to IBD, but our soy protein treatment prevented 
the increased in osteocytes positive for annexin V. Therefore, our data indicates our soy protein 
diet decreased osteocyte apoptosis, which also may contribute to the reduced recruitment of 
osteoclast surface in the IBD rats with the moderately elevated soy protein diet.  
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 Our original hypothesis was that the soy protein would act as an anti-inflammatory 
agent and the moderate elevation in protein content in the diet would act to increase bone 
formation potentially due to an increase in insulin-like growth factor-I (IGF-I). Our original 
hypothesis was supported in that the moderately elevated soy protein intervention during IBD 
reduced pro-inflammatory markers and increased bone formation rate; however, we cannot 
conclude that osteocyte IGF-I played a role in this effect. Serum IGF-I is decreased in patients 
with IBD (31), but we previously demonstrated that osteocyte IGF-I was, in fact, elevated in 
TNBS rats along with elevations in pro-inflammatory markers (17). Osteocyte IGF-I has mostly 
been examined in response to increased or decreased mechanical loading on bone (32, 33, 34) 
and the role of osteocyte IGF-I in inflammatory states is unknown. In this current study, we 
found similar elevations in IGF-I-positive osteocytes due to TNBS, but a 35% decrease in 
osteocytes positive for IGF-I in TNBS animals fed the soy protein diet, returning to levels similar 
to vehicle controls. The moderately elevated soy protein diet did increase bone formation rate, 
but our data provide no support for osteocyte IGF-I as a mechanism for these observed changes. 
 We did not find differences in bone mass or cancellous microarchitecture due to IBD 
or to the dietary intervention. The inflammatory insult with TNBS instillation in our experiment 
did not cause serious side effects like rapid weight loss or altered eating patterns as many other 
animal studies using induced IBD find, but the resulting changes in gut and bone are consistent 
with a pro-inflammatory state that, if it continued over a longer period, would undoubtedly result 
in bone loss. While we could not detect changes in bone mass over the four weeks of this 
experiment, the elevated resorptive and decreased formation activity indicate what would likely 
become progressive bone loss in IBD and a mitigation of bone loss or preservation of bone mass 
with the soy protein intervention. Additionally, since our animals had no changes in body weight 
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or food intake, we hypothesize the changes in bone and the colon observed in TNBS rats that 
were mitigated by the soy protein diet are due to inflammation and not malnutrition or poor 
nutrient absorption. Since IBD is a chronic condition that often develops in childhood or young 
adulthood, even a mild inflammation like that of our rats would result in bone loss over time and 
increased fracture risk.  
 In conclusion, this study demonstrated that a moderately elevated soy protein diet 
during chronic IBD in young male rats mitigated the inflammation-induced increases in 
osteoclast surfaces and decreases in bone formation rate. Additionally, osteocyte proteins 
reflected a shift away from a pro-inflammatory state resulting in reductions in bone specific 
proteins responsible for controlling osteoclast formation and inhibiting osteoblasts. Therefore, 
our data show potential for a dietary intervention that could be used in conjunction with other 
therapies to beneficially alter the inflammatory insult during this chronic disease. 
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4. EXOGENOUS TREATMENT WITH IRISIN PREVENTS INFLAMMATORY BONE 
CHANGES DURING CHRONIC TNBS-INDUCED INFLAMMATORY BOWEL 
DISEASE 
Exercise has long been lauded as anti-inflammatory; however, the exact mechanism by 
which exercise exerts immunological change or the specifics of those immunological changes 
remains largely unknown. Increasing levels of physical activity are associated with lower C-
reactive protein (1); however, data from large controlled studies examining inflammatory factors 
influenced by exercise are lacking (2). Despite the lack of empirical evidence demonstrating the 
anti-inflammatory benefits of exercise, exercise has been recommended in multiple 
inflammatory conditions including inflammatory bowel disease (3). A couple small intervention 
studies found moderate walking exercise improved IBD symptoms (4, 5). Another study found 
Crohn’s disease patients in remission engaging in higher levels of exercise activity were less 
likely to develop active disease (6). Correlational evidence also shows relationships between 
physical activity and the development of IBD, with sedentary occupations correlated with higher 
incidence of IBD (7) and participation in a lower number of childhood sports also associated 
with increased risk of developing IBD (8). The relative risk of Crohn’s disease is inversely 
related to regular physical activity (9). Combined, these studies suggest there may be a 
preventive effect of regular exercise in the development of IBD and a potential mitigation of 
inflammation due to exercise during IBD. An understanding of what factors are released during 
exercise and their exact roles in immune function and inflammatory processes could lead to 
novel therapeutic targets for treating IBD as well as specified exercise training programs targeted 
to mitigating disease symptoms. 
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Irisin, a protein released from exercising muscle due to an increase in peroxisome 
proliferator-activated receptor γ coactivator-1α (PGC-1α), has recently emerged as a potential 
modulator of exercise-related physiological adaptations (10). Originally proposed to be a 
myokine, evidence indicates irisin could be released from other tissues including adipose and 
cardiac muscle (11, 12). Irisin was originally defined as a mediator of increased metabolism due 
its induction of uncoupling protein-1 (UCP-1) in white adipose leading to the browning of white 
adipose (10). Following acute exercise, irisin is elevated in serum in humans, rats, and mice (10, 
11, 13). Young male rats exposed to 10 minutes of stressful exercise via water floating had 
approximately 75% increases in serum irisin compared to control non-exercised rats (11). Three 
weeks of free wheel running in mice followed by 12 hours of rest revealed approximately 66% 
higher irisin present in the plasma of exercised mice (10). Serum irisin was approximately 60% 
higher after acute submaximal treadmill running in mice compared to control levels (13). 
Following 10 weeks of cycle training (4-5 sessions/week for 20-35 minutes/session at 
approximately 65% of maximal oxygen consumption) in male humans, plasma irisin increased 
by approximately 75% compared to baseline (10). It remains uncertain whether there are chronic 
adaptations of irisin to exercise training or if irisin only transiently increases after a bout of 
exercise. One study found serum irisin to increase after heavy resistance exercise or aerobic 
training, but returned to baseline several hours after exercise (14).  
Interestingly, aside from irisin’s originally proposed actions in metabolism, several 
studies have shown decreased serum irisin in conditions with inflammatory components. In 
chronic kidney disease where circulating pro-inflammatory markers predict disease stages (15), 
serum irisin levels decrease with increasing severity of disease (16). Likewise, type 2 diabetes, 
which is characterized by chronic systemic low grade inflammation (17), is associated with low 
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serum irisin (18). Finally, in an animal model of chronic heart failure, there is a negative 
correlation between circulating irisin and circulating TNF-α (19). Additionally, recent studies 
have demonstrated exogenous irisin treatment improved inflammatory outcomes in rodent 
models of atherosclerosis (20), ischemic stroke (21), and LPS-induced lung injury (22). Irisin has 
also recently emerged as a bone anabolic factor stimulating osteoblast proliferation and increased 
bone formation rate (23, 24, 25). The role of irisin in preventing inflammation-induced bone 
alterations has not yet been explored nor has the use of irisin as a therapeutic agent for chronic 
IBD. 
The goal of this current project is to examine exogenous irisin treatment during chronic 
IBD in a rodent model. We hypothesized intraperitoneal injections of irisin after establishment of 
TNBS-induced gut inflammation would mitigate the pro-inflammatory response in bone. 
Specifically, we hypothesized that exogenous irisin treatments would increase bone formation 
rate and decrease osteoclast surfaces. These changes in bone turnover would correspond with 
decreased osteocyte TNF-α, IL-6, RANKL, OPG, and sclerostin. Additionally, we hypothesized 
irisin treatments during TNBS would restore osteocyte IGF-I levels to that of vehicle-treated rats.  
4.1 Materials and Methods 
Animals: Thirty-two male Sprague-Dawley rats (1.5 months old) were ordered from 
Envigo (Houston, Texas) and singly housed in an institutionally approved animal facility with 12 
hour light:dark cycles.  Animals were allowed approximately four days to acclimate to the 
facility before being switched from standard rodent chow (Teklad 2018, Envigo) to the purified 
AIN93G chow (Research Diets, Inc., New Brunswick, NJ). Animals were allowed free access to 
food and water. Following the one-week acclimation to the diet, animals were randomly divided 
into four different groups (n=8/group): Vehicle (Veh), Vehicle with irisin (Veh+Ir), IBD induced 
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via 2,4,6-trinitrobenzenesulfonic acid (TNBS), and IBD with irisin (TNBS+Ir). Rectal 
instillations of either 2,4,6-trinitrobenzenesulfonic acid (TNBS) in 30% ethanol or 30% ethanol 
(for Veh) began at 2 months of age and continued for four weeks. Instillations occurred once per 
week with the fifth and final instillation occurring 3-4 days prior to termination. Intraperitoneal 
irisin injections were delivered, 2x per week beginning the second week of instillations, for a 
total of six injections. Fluorochrome calcein labels (Sigma Aldrich, St Louis, MO) were injected 
intraperitoneally 8 and 3 days prior to termination to label mineralized surfaces on bone. Animal 
health was monitored daily and food intake and bodyweight were measured several times per 
week for the entire experimental period. After four weeks of TNBS or Veh treatment, rats were 
anesthetized via inhaled vaporized isoflurane, euthanized via thoracotomy, and tissues were 
collected. All animal procedures were approved by the Texas A&M Institutional Animal Use and 
Care Committee and confirm to the NIH Guide for the Care and Use of Laboratory Animals. 
Rectal Instillations: Gut inflammation was induced by rectal instillations of 1 uL/gram body 
weight rectal of 2,4,6-trinitrobenzenesulfonic acid (TNBS; Sigma Aldrich, St Louis, MO) in 30% 
ethanol:DiH2O solutions as previously described (26). Instillations were given at days 1, 7, 14, 
21, and 26 of the experimental period to non-fasted rats anesthetized via inhaled isoflurane with 
a precision vaporizer.  
Irisin Injections: Recombinant irisin (Adipogen Life Sciences, San Diego, CA) was 
dissolved in sterile phosphate buffered saline. Doses of 18 ng/mL dissolved in sterile phosphate-
buffered saline (2 µL) were injected intraperitoneally into all irisin treated rats. Previous work of 
ours identified normal circulating levels of irisin in serum in rats of the same age and strain from 
the same vendor to be 6 ng/mL. Therefore, our goal was to provide 4x that of normal circulating 
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levels. Irisin-treated rats received two doses per week (3.5 days apart) for 3 weeks. The first 
irisin dose coincided with the second rectal instillation. 
Dynamic and Static Histomorphometry: Undemineralized right proximal tibia and 
fourth lumbar vertebrae (L4) were fixed in 4% phosphate buffered formalin and then subjected to 
serial dehydration and embedded in methyl methacrylate (J.T. Baker, VWR, Radnor, PA). Serial 
frontal sections at 8 µm thickness were left unstained for analysis of fluorochrome labels for 
dynamic bone formation rate (BFR). All analyses were completed on OsteoMeasure Analysis 
System, version 3.3 (OsteoMetrics, Inc., Atlanta, GA). For the proximal tibia, a defined region of 
interest was established approximately 500 µm from the growth plate and within the endocortical 
edges encompassing approximately 8 mm2 at 20x magnification. For L4, a region was defined 
500 µm above the end of the bone within endocortical edges at approximately 3 mm2 at 20x 
magnification. For 8 µm sections, total bone surface (BS), single-labeled surface (sLS/BS), 
double-labeled surface (dLS/BS), mineralized surface (MS/BS), and inter-label distances were 
measured at 20x magnification (Figure 4.1). Mineral apposition rate (MAR) was calculated from 
the inter-label distance and time of labels. Bone formation rate (BFR/BS) was determined by 
multiplying MS/BS by MAR. Further frontal sections of the proximal tibia and L4 were 
sectioned at 4 µm thickness treated with a Von Kossa stain with a tetrachrome counterstain. 
These sections were measured at 40x magnification for identification of osteoclast surface 
(OcS/BS) and osteoid surface (OS/BS). All analyses were completed by the same individual to 
ensure consistency in measures. All nomenclature for cancellous histomorphometry follows 
standard usage (27).   
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Figure 4.1: Identification of single vs. double fluorochrome labels on cancellous bone.  
 
Immunohistochemistry of Osteocyte Proteins: Left distal femurs were fixed in 4% 
phosphate buffered formalin and then stored in 70% ethanol. Tissues then underwent 
decalcification in a formic acid/sodium citrate solution for approximately 18 days. Sections were 
then further dehydrated in Thermo-Scientific STP 120 Spin Tissue Processor, paraffinized via a 
Thermo Shandon Histocenter 3 Embedding tool. Frontal sections at 8 µm thickness were 
mounted on positively charged slides and immunostained using an avidin-biotin method as 
previously described (26). Incubation occurred with the following primary antibodies: polyclonal 
rabbit anti-rat TNF-α, (LifeSpan BioSciences, Inc, Seattle, WA), polyclonal rabbit anti-IL-6 
(Abcam, Cambridge, MA), polyclonal rabbit anti-IL-10 (Abcam, Cambridge, MA), polycloncal 
rabbit anti-IL-4 (Abcam, Cambridge, MA), polyclonal rabbit anti-annexin V (Abcam, 
Cambridge, MA), polyclonal goat anti-mouse sclerostin (R&D Systems, Minneapolis, MN), 
polyclonal rabbit anti-annexin V (Abcam, Cambridge, MA). All sections were counterstained 
with methyl green. Sections were analyzed as the percentage of osteocytes stained positively for 
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the protein with a 4 mm2 region in the distal femur cancellous bone compartment approximately 
500 µm away from the growth plate and excluding endocortical surfaces. All analyses were 
completed by the same individual. Previous data demonstrated the cancellous bone region is the 
bone site that responds most vigorously to inflammation due to IBD (26). 
Statistical analyses: All data were tested for homogeneity and analyzed using a 2x2 
factorial ANOVA to determine main effects of irisin and TNBS.  If an irisin-by-TNBS 
interaction was present (p<0.05), all-groups analysis was completed. If the main effects were 
significant (p<0.05), a Duncan post-hoc test was used to determine differences between groups. 
Statistical analyses were completed on SPSS (IBM; Armonk, NY).  All data are represented as 
mean ± standard deviation.   
4.2 Results 
All animals maintained bodyweight and consistent food intake across the course of the 
study regardless of TNBS or irisin treatment. There were no statistical differences in bodyweight 
between any groups at any time point in the study. Additionally, food intake was not different 
due to any treatment.   
Exogenous irisin treatment mitigated gut damage and inflammation during chronic 
TNBS. There were significant main effects for TNBS treatment, irisin, and a significant TNBS-
by-irisin interaction (p<0.0001 for all) on histopathological scores. The TNBS group was higher 
than all other groups, with both Veh groups no different from the TNBS+Ir group (Figure 4.2). 
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Figure 4.2: Colon histopathology. TNBS had the highest aggregated score with TNBS+Ir no different from either 
vehicle-treated group. *Indicates different from all other groups. 
 
 
 
Irisin decreased osteoclast surface at both the proximal tibia and L4 regardless of gut 
inflammation. At the proximal tibia, there was a main effect of irisin (p<0.0001) and an 
interaction effect (p=0.045), but no main effect of TNBS treatment (p=0.278). At this bone site, 
TNBS animals had the highest osteoclast surface followed by vehicle-treated rats.  TNBS+Ir rats 
had the lowest osteoclast surface with Veh+Ir animals no different from those in Veh or 
TNBS+Ir groups. At L4, there was also a significant main effect of irisin (p<0.0001) and an 
interaction effect (p=0.031), but no main effect of TNBS treatment (p=0.141). At L4, TNBS rats 
had the highest osteoclast surface followed by Veh animals, with both irisin groups having the 
lowest osteoclast surface (Figure 4.3A).  
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Figure 4.3: Osteoclast and osteoid surfaces on cancellous bone of the proximal tibia and 4th lumbar vertebrae. (A) 
Osteoclast surface was highest in TNBS in the proximal and lowest in both Ir groups. In L4, osteoclast surface was 
highest in TNBS and both Ir groups were lower than Veh. (B) Osteoid surface was lower in TNBS in both the 
proximal tibia and L4. TNBS+Ir was no different than Veh. *Indicates different from all other groups. Bars not 
sharing the same letter are statistically different. 
 
 
 
Exogenous irisin caused a robust increase in bone formation rate in all animals 
regardless of gut inflammation. At the proximal tibia, there were significant main effects of 
TNBS treatment and irisin (p<0.0001 for both), but no interaction effect (p=0.738). BFR was 
lowest in TNBS with both irisin-treated groups having BFR higher than Veh rats (Figure 4.4A). 
For mineralizing surface, there were significant effects of TNBS treatment (p=0.006) and irisin 
(p<0.0001) and an interaction effect (p=0.006). Both irisin groups had the highest MS/BS with 
TNBS having the lowest (Figure 4.4B). For mineral apposition rate, there were main effects for 
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TNBS treatment (p=0.001) and irisin (p<0.0001), but no interaction (p=0.927). MAR was lowest 
in the TNBS group with the TNBS+Ir having MAR higher than Veh rats (Figure 4.4C). For BFR 
at L4, there were main effects of TNBS treatment (p=0.01) and irisin (p<0.0001), but no 
interaction effect (p=0.912). BFR was higher in both irisin groups than Veh and TNBS (Figure 
4.4A). For mineralizing surface at L4, there were main effects of TNBS treatment (p=0.008) and 
irisin (p<0.0001), but no interaction (p=0.175). MS/BS was lowest in the TNBS group with the 
TNBS+Ir group not statistically different from Veh rats (Figure 4.4B). For MAR at L4, there 
were also main effects of TNBS treatment (p=0.029) and irisin (p<0.0001) and no interaction 
effect (p=0.912). MAR was greater in both irisin-treated groups compared to Veh and TNBS 
(Figure 4.4C). Osteoid surface showed reversal of depressed osteoid due to gut inflammation in 
the irisin-treated groups. At the proximal tibia, there were main effects of TNBS treatment 
(p=0.018), irisin (p=0.003), and a significant interaction effect (p=0.011). TNBS had the lowest 
osteoid surface of all groups. At L4, there were significant effects of TNBS treatment (p=0.002), 
irisin (p<0.0001), and an interaction effect (p<0.0001). At L4, similar to the proximal tibia, 
TNBS had the lowest osteoid surface of all groups (Figure 4.3B).  
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Figure 4.4: Cancellous bone formation rate at the proximal tibia and L4. (A) Bone formation rate was highest in 
Veh+Ir, followed by TNBS+Ir. TNBS alone had the lowest BFR. (B) Mineralized surface was highest in both Ir 
treated groups in both sites followed by Veh with TNBS having the lowest BFR. (C) MAR at the proximal tibia was 
highest in Veh+Ir with TNBS+Ir no different than Veh and TNBS having the lowest MAR. At L4, both Ir groups 
had the highest MAR. Bars not sharing the same letter are statistically different. 
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Exogenous irisin treatment reduced pro-inflammatory cytokines in osteocytes and 
altered regulators of bone turnover. TNF-α: There were significant main effects of both TNBS 
treatment (p=0.001) and irisin (p<0.0001) on %TNF-α+ osteocytes as well as a significant 
interaction effect (p=0.001). The TNBS group had the highest TNF-α followed by Veh with both 
irisin groups having the lowest %TNF-α+ osteocytes (Figure 4.5A). IL-6: For %IL-6+ osteocytes 
there was a main effect for both TNBS treatment and irisin (p<0.0001 for both), but no 
interaction effect (p=0.123). TNBS rats had the highest IL-6+ osteocytes followed by Veh. 
Veh+Ir had the lowest IL-6 with TNBS+Ir no different from Veh or Veh+Ir (Figure 4.5B). 
IL-4: There was no main effect of treatment on IL-4+ osteocytes (p=0.074), but a significant 
effect of irisin treatment (p<0.0001) and an interaction effect (p=0.023). Vehicle rats had the 
highest IL-4+ osteocytes followed by TNBS rats with both irisin-treated groups having the 
lowest IL-4+ osteocytes (Figure 4.5C). IL-10: There was only a main effect of irisin on IL-10+ 
osteocytes (p<0.0001). There was no effect of TNBS treatment (p=0.914) or an interaction 
(p=0.425). IL-10+ osteocytes were lower in both irisin-treated groups (Figure 4.5D). RANKL: 
There were significant main effects of TNBS treatment and irisin (p<0.0001 for) and a 
significant interaction effect (p=0.002) for RANKL-positive osteocytes. The TNBS group had 
higher RANKL-positive osteocytes than all other groups (Figure 4.6A). OPG: Main effects for 
TNBS treatment, irisin, and treatment-by-diet were present in OPG+ osteocytes (p<0.0001 for 
all). TNBS rats had the highest OPG-positive osteocytes of all groups (Figure 4.6B). 
IGF-I: There was a significant main effect of only irisin treatment on IGF-I-positive osteocytes 
(p<0.0001) with non-significant effects of TNBS treatment (p=0.094) and TNBS-by-irisin 
interaction (p=0.056). The TNBS group had the highest osteocyte IGF-I followed by Veh rats 
with both irisin-treated groups having the lowest %IGF-I+ osteocytes (Figure 4.6C). Sclerostin: 
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There was a main effect of both TNBS treatment (p=0.001) and irisin (p<0.0001) as well as an 
interaction effect (p=0.042). TNBS rats had the highest levels of sclerostin-positive osteocytes 
followed by Veh rats. The Veh+Ir group had the lowest %sclerostin+ osteocytes with TNBS+Ir 
rats no different from either Veh or Veh+Ir (Figure 4.6D). Annexin V: For annexin V-positive 
osteocytes, a marker of cell undergoing apoptosis, there were main effects of TNBS (p=0.008), 
irisin treatment (p<0.0001), and an interaction (p=0.003). TNBS rats had higher annexin V-
positive osteocytes than all other groups (Figure 4.6E). 
 
 
Figure 4.5: Immunohistochemistry for inflammatory proteins in osteocytes in the cancellous bone of the distal 
femur. (A) TNF-α-positive osteocytes were highest in TNBS with both Ir treated groups lower than Veh. (B) IL-6-
positive osteocytes were highest in TNBS with TNBS+Ir no different from Veh or Veh+Ir. (C) IL-4-positive 
osteocytes were lower in TNBS vs.Veh, but both Ir groups were lower than TNBS. (D) Both Ir groups had lower IL-
10-positive osteocytes than Veh and TNBS. Bars not sharing the same letter are statistically different.  
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Figure 4.6: Immunohistochemistry for osteocyte proteins in the distal femur cancellous bone. (A) RANKL-positive 
osteocytes were elevated in TNBS, but TNBS+Ir was no different from Veh. (B) OPG-positive osteocytes were 
higher in TNBS than any other group. (C) IGF-I-positive osteocytes were highest in TNBS with both Ir treated 
groups lower than Veh. (D) Sclerostin-positive osteocytes were highest in TNBS with TNBS+Ir no different from 
Veh or Veh+Ir. (E) Annexin V-positive osteocytes were highest in TNBS with TNBS+Ir no different than either 
Veh group. (F) Representative image of immunohistochemistry of osteocytes in cancellous bone. *Indicates 
different from all other groups. Bars not sharing the same letter are statistically different.  
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4.3 Discussion 
 The primary findings of this study are that exogenous treatment with the exercise-
related myokine, irisin, ameliorated gut inflammation in chronic IBD, reversed inflammation-
induced changes in bone turnover, and altered osteocyte proteins. We found that exogenous irisin 
treatments reduced bone-specific, pro-inflammatory markers and significantly stimulated bone 
formation rate. 
 Our analyses of the colons of TNBS rats demonstrated that irisin treatment completely 
mitigated the edema, crypt cell loss, and increased cellularity seen in the TNBS-treated animals. 
The IBD rats with irisin treatment had colon structure and cellularity no different from all 
vehicle- treated rats. The role of irisin on gut physiology, healthy or diseased, has not been 
explored, but our data indicate that irisin acts to reduce the inflammatory insult of TNBS in the 
gut. 
 Irisin has recently been introduced as a bone anabolic factor. Cell culture studies have 
revealed increased osteoblast proliferation and differentiation with irisin treatment (24, 25). 
Additionally, injections of recombinant irisin into healthy mice resulted in increased periosteal 
bone formation rate (23) and increased trabecular and cortical osteoblast numbers (25). Our rats 
had robust increases in cancellous bone formation rate with approximately 1- to 2-fold higher 
BFR at the proximal tibia and 1.5- to 3.6-fold higher BFR at L4, regardless of TNBS treatment. 
These increases in BFR were due to increases in both mineralized surface and mineral apposition 
rate indicating both an increase in recruitment of osteoblasts and increased activity of those 
osteoblast teams. Interestingly, there were TNBS-by-irisin interaction effects only in mineralized 
surface, with mineralized surface no different between Veh+Ir and TNBS+Ir groups, but there 
were no interactions in MAR or BFR where the TNBS+Ir group was still lower than Veh+Ir rats. 
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This indicates that exogenous irisin treatment may prevent the suppression of osteoblast 
recruitment (MS/BS) during inflammation, but may not completely alleviate the suppression on 
the activity (MAR) of those osteoblasts. However, it must be noted that BFR was still higher in 
IBD rats treated with irisin compared to vehicle controls (~50% higher at the proximal tibia and 
~95% higher at L4). Therefore, our data clearly demonstrate the anabolic actions of irisin on 
bone. 
With regards to bone resorption, in vitro studies have found irisin decrease RANKL-
induced osteoclastogenesis (25) and treatment with exogenous irisin decreased bone resorption 
(23). In our study, we found declines in osteoclast surface due to exogenous irisin treatment 
(51% lower in TNBS+Ir vs TNBS at the proximal tibia and 61% lower at L4). Irisin treatment 
completely prevented the increase in osteoclast surface seen due to IBD. Additionally, osteoclast 
surfaces were lower in both irisin-treated groups than in vehicle-treated rats (26-41% lower). 
Therefore, we demonstrated for the first time that irisin treatment can prevent inflammation-
induced increases in osteoclast-resorbing surfaces. 
 Our key hypothesis was that irisin treatment would prevent inflammatory bone 
changes by decreasing pro-inflammatory cytokines. A few other recent studies show that 
exogenous irisin treatment can reduce pro-inflammatory cytokines in various inflammatory 
conditions. In a model of ischemic stroke, exogenous irisin administration reduces the magnitude 
of the re-perfusion injury and expression of TNF-α and IL-6 mRNA (21). Likewise, in LPS-
induced lung injury, treatment with irisin is protective and reduces the production of multiple 
pro-inflammatory cytokines including TNF-α and IL-6 (20). Finally, irisin reduces vascular 
inflammation in atherosclerotic mice (22). In our study, exogenous irisin treatment reduced TNF-
α-positive osteocytes by 85% and IL-6-positive osteocytes by 55% in TNBS animals. These 
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osteocyte-specific data match previous work in other animal models demonstrating the effect 
irisin has in reducing pro-inflammatory cytokines. Importantly, these changes in osteocyte pro-
inflammatory cytokines correspond with decreased osteoclast surfaces and increased bone 
formation rate. Additionally, we examined two Th2 cytokines, IL-10 and IL-4, and found both 
were significantly reduced due to irisin treatment, indicating a potential for irisin modulating 
both Th1- and Th2-related cytokines. As previously mentioned, the role of Th2 cytokines in bone 
cells is largely unknown and we cannot speculate what these alterations due to irisin mean for 
bone homeostasis. Our data indicate a clear immunological modulation via irisin resulting in 
reductions in pro-inflammatory cytokines. 
 With regard to bone-specific factors, in vitro experiments reveal decreased RANKL-
induced osteoclastogenesis due to irisin treatment (25). Furthermore, recombinant irisin 
administration in mice leads to decreased SOST expression, the gene for sclerostin (23). We, 
however, are the first to examine specific osteocyte protein response to exogenous irisin 
treatment. RANKL-positive osteocytes were 4.5-fold lower in TNBS+Ir compared to the TNBS 
alone animals. Likewise, OPG, the decoy receptor for RANKL, was approximately 6-fold lower 
in TNBS animals treated with irisin. Since both RANKL and OPG are regulated in part by TNF-
α and are the key regulatory step in osteoclastogenesis, the reduction in TNF-α and the reduction 
in osteoclast surfaces is consistent with our data demonstrating reduced RANKL and OPG. TNF-
α also regulates sclerostin, leading to our hypothesis that sclerostin would be reduced due to 
irisin treatment. Our data confirm our hypothesis, with the percentage of sclerostin-positive 
osteocytes nearly 2-fold lower in irisin-treated TNBS animals than TNBS alone rats. Our 
sclerostin data correspond with the robust increase in bone formation rate and mineralizing 
surface, since sclerostin is a negative regulator of osteoblastogenesis. Additionally, we found 
 106 
 
irisin treatment prevented the increase in annexin V in osteocytes indicating normalized 
apoptosis rates which is also likely due to the decrease in TNF-α and matches our data showing 
lower osteoclast levels. Due to our previous data showing the confounding data with osteocyte 
IGF-I, we hypothesized that irisin treatment would return osteocyte IGF-I to vehicle levels, but 
our data revealed IGF-I-positive osteocytes were lower in both irisin treated groups than in 
vehicle rats. Since irisin is clearly an anabolic factor inducing an increase in bone formation rate 
and osteocyte IGF-I is known to induce osteoblasts in conditions of increased loading (28, 29, 
30), the current data indicate that we do not yet understand the complexities of osteocyte IGF-I, 
its role in inflammatory-related conditions, nor its potential interaction with irisin. Nonetheless, 
our data indicate that irisin treatment alters osteocyte-specific proteins and, in the case of 
inflammatory bone changes, beneficially alters proteins to favor bone formation and decreased 
bone resorption. 
 Similar to our previous work with soy protein interventions, our animals in this study 
did not show any differences in body weight, food intake, bone mineral density, or cancellous 
microarchitecture. As previously discussed, our model create a modest inflammatory insult; 
however, over the long term the changes in bone turnover we see in our TNBS animals would 
lead to bone loss. Additionally, our irisin treatment did not show changes in bone mass. Due to 
the slow nature of bone adaptations, the changes in bone turnover markers with irisin treatment 
indicate that with time there would likely be increased bone mass. 
 Our data indicate that exogenous irisin treatment acts to decrease pro-inflammatory 
cytokines and, consequently, reverse inflammatory-induced changes in bone turnover. Since 
irisin is increased during exercise, targeted exercise therapies to increase irisin could potentially 
be created to treat inflammatory conditions like IBD; however, the question is if irisin is a major 
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factor driving immunological changes during exercise. To examine this, Li et al injected 
exercising mice with a neutralizing antibody for irisin prior to ischemic injury and found those 
mice had more profound neuronal injury than exercising mice injected with control IgG (21). 
Therefore, it is reasonable to hypothesize that irisin is, in fact, a major driver of the so-called 
“anti-inflammatory” effects of exercise. It is important to note that most studies examining 
exercise-induced changes demonstrate only a modest (60-75%) magnitude of acute exercise-
induced increase in serum irisin with the training protocols utilized (10, 11, 13). In our study, rats 
were injected twice weekly with a dose 4-times that of circulating levels, potentially resulting in 
an increase greater than with exercise training protocols. Therefore, studies to determine the 
amount and type of exercise needed to naturally induce changes in serum irisin to achieve similar 
changes in inflammatory markers are needed. Also, it must be noted that exercise is a complex 
physiological process and there may be a host of other factors released during exercise that either 
enhance or depress the influence of irisin. Our data indicate that exogenous irisin, reverses 
chronic inflammatory bone changes, highlighting the potential therapeutic effect of both 
exercise-induced and exogenous irisin. 
 In conclusion, this study demonstrates for the first time that exogenous irisin treatment 
during chronic inflammatory bowel disease preserved normal gut morphology, induced an 
increase in bone formation rate, and suppressed osteoclast surfaces. Additionally, irisin treatment 
impacted the inflammatory response of bone by reducing osteocyte pro-inflammatory markers as 
well as bone-specific regulators of bone turnover. Overall, irisin treatment reversed the 
inflammatory-induced changes in bone seen with IBD alone. Therefore, our data indicate that 
irisin may be a key regulatory mediator of the proposed anti-inflammatory effects of exercise, 
suggesting that targeted exercise regimens designed to maximize increases of circulating irisin 
 108 
 
may prove to be beneficial for individuals with chronic systemic inflammatory conditions like 
IBD. Secondly, our data indicates that irisin administration, alone, could be a novel therapy for 
chronic inflammatory conditions and a potential treatment for inflammation-induced bone loss. 
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5. CONCLUSIONS 
 Together these studies demonstrate that 1) chronic inflammatory bowel disease leads 
to inflammatory-induced changes in bone turnover and a pro-inflammatory response of 
osteocytes, 2) a moderately elevated soy protein diet can mitigate the pro-inflammatory state of 
osteocytes as well as inflammation-induced changes in bone turnover, and 3) irisin, an 
adipomyokine released during exercise, alleviates the inflammatory state of bone during chronic 
IBD and altered osteocyte protein response. 
 To date, the role of osteocytes in inflammation-induced bone loss has been neglected. 
While inflammation is known to lead to an increase in bone resorption and a decrease in bone 
formation, whether or not osteocytes play a role in regulating these changes has not been 
addressed. In our model of chronic inflammatory bowel disease, there was an increase in 
osteocytes positive for multiple pro-inflammatory cytokines (TNF-α and IL-6) as well as many 
factors activated by TNF-α (RANKL, OPG, sclerostin; Figure 5.1). These changes in osteocyte 
proteins strongly predicted the increases in osteoclast surfaces and declines in bone formation 
rate in IBD rats. These data indicate that osteocytes respond to systemic signals of inflammation. 
Similar to conditions of mechanical loading or unloading where osteocytes are known to play a 
key regulatory role, osteocytes may also be orchestrating the changes observed in bone turnover 
due to systemic inflammation. 
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Figure 5.1: Influence of pro-inflammatory factors on bone cells during chronic IBD. Together these alterations lead 
to an increase in bone resorption and a decrease in bone formation. Our data indicate that all these factors are either 
expressed or bind to osteocytes. 
 
 
 
 With current treatments for IBD all aiming to simply mitigate the disease symptoms 
often with negative side effects, there is a need for lifestyle interventions that can mitigate 
inflammation, thus lessening the need for medications or enhancing the influence of concurrent 
treatments. In our second study, we examined the use of a moderately elevated soy protein diet 
during chronic IBD and discovered it successfully mitigated the inflammatory-induced changes 
in gut structure and the pro-inflammatory status of osteocytes, as well as decreased osteoclast 
surfaces and increased bone formation rate. In most all of our measures, the IBD animals with 
the soy protein intervention had values no different from their vehicle-treated controls. 
Additionally, the beneficial changes in bone turnover were all concurrent with alterations in 
osteocyte proteins, again alluding to a potential key regulatory role of osteocytes in inflammatory 
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conditions. The mechanisms by which the effects of the soy protein diet influenced the GI and 
bone inflammation remain to be determined (Figure 5.2). 
 
 
Figure 5.2: Intervention of soy protein during chronic IBD. Moderately elevated soy protein during chronic IBD 
resulted in decreases in key pro-inflammatory factors, osteoclastogenesis factors, and osteoblast inhibitors. The soy 
protein intervention mitigated osteoclast surfaces and increased bone formation. 
 
 
 
 Although exercise has long been lauded as anti-inflammatory, there is minimal 
evidence of what factors may actually be inducing such a change or what type of immunological 
change is occurring due to exercise. In our final study, we explored the use of exogenous 
treatment with irisin, a factor released during exercise, during chronic IBD. We discovered that 
exogenous irisin mitigated the inflammatory insult in both the gut and the bone. Irisin treatment 
lead to an increase in bone formation rate and a concurrent decrease in osteoclast surfaces 
beyond those of vehicle-treated rats. These changes in bone turnover were concurrent with 
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declines in pro-inflammatory factors, osteoclastogenesis regulators, and osteoblast inhibitors in 
osteocytes (Figure 5.3).  
 
Figure 5.3: Actions of exogenous irisin administration during chronic IBD. Exogenous irisin administration resulted 
in declines in TNF-α, IL-6, RANKL, OPG, and sclerostin. These changes were concurrent with increased bone 
formation rate and decreased osteoclast surfaces. 
 
 
 
 In conclusion, our data demonstrate that osteocytes may be regulators of 
inflammation-induced bone loss and, therefore, treatments that alter osteocyte proteins may be 
key therapeutic targets for diseases impacting bone. Additionally, we found that both a 
moderately elevated soy protein diet and exogenous treatment with irisin successfully mitigated 
the pro-inflammatory status of bone and attenuated or reversed inflammation-induced changes in 
bone turnover. Therefore, a soy protein diet may be useful as a simple and cost effective lifestyle 
addition for patients with IBD. Regular exercise therapy may also be able to aid in protection 
against the inflammatory insult of chronic IBD and weight-bearing exercise would have the 
added benefit on bone of increasing mechanical loads. Finally, exogenous irisin may also be a 
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novel anti-inflammatory therapeutic for IBD and other chronic systemic inflammatory 
conditions.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
